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Oligodendrocytes (OLs) are the myelin-forming cells of the central nervous system 
(CNS). They synthesize large amounts of plasma membrane and extends multiple 
processes that individually wrap around axons generating a multilayered stack of 
membranes tightly attached at their cytosolic and external surfaces [1], i.e. myelin. The 
myelin membrane provides electric insulation of axons and dictates the clustering of the 
sodium channels at the nodes of Ranvier and the organization of the node itself, 
allowing saltatory nerve conduction [2, 3]. A number of neurological diseases of the 
CNS are characterized by destruction of oligodendrocytes with consequent damage or 
loss of the myelin sheath. In most experimental models, the normal response to this is 
remyelination, a process mediated by oligodendrocyte precursor cells (OPC) that 
ultimately leads to functional recovery. However in human diseases, and in specific in 
multiple sclerosis (MS), this process is inefficient and fails to successfully counteract 
the accumulation of lasting axonal damage and increasing brain atrophy, thus resulting 
in motor and neurological deficits [4, 5]. The development of strategies aimed to 
increase the efficiency of the remyelination process is therefore an important therapeutic 
goal. One of these strategies involves the use of CNS reactive antibodies to promote 
remyelination [6]. One of these antibodies, rHIgM22, is able to bind to 
oligodendrocytes and myelin in vitro. Moreover, rHIgM22 is able to enter the CNS, 
accumulate at lesion site and promote remyelination in mouse models of chronical 
demyelination [7, 8]. As a matter of fact, this antibody has recently passed a phase I 
clinical trial for treatment of MS.  
rHIgM22 binds to CNS tissues with a pattern very similar to that of the anti-sulfatide 
antibody O4 [9], and binding of rHIgM22 is abolished in CNS tissue slices from CST (-
/-) mice [10], suggesting that rHIgM22 binding to myelin requires the presence of a 
product of cerebroside sulfotransferase, possibly sulfatide. However the exact identity 
of the antigen recognized by this antibody remains to be elucidated. The binding of 
rHIgM22 to purified lipids and to lipid extracts from various sources, including wild 
type, ASM (-/-), CST (+/-) and CST (-/-) mice brains, mouse mixed glial cells (MGC), 
mouse astrocytes, rat rHIgM22+ oligodendrocytes (OL), rat microglia, and mouse 
myelin, has been tested using TLC immunostaining assays and SPR experiments with 
lipid monolayers with different composition. 
The results obtained show that rHIgM22 binds to sulfatide, and, to a lesser extent, to 
lysosulfatide in vitro, while it does not bind to other myelin sphingolipids, including 
galactosylceramide and sphingomyelin, suggesting that sulfatide at the oligodendrocyte 
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surface might be important for the binding of rHIgM22 to the surface of these cells and 
to myelin. The binding affinity for both sulfatide and its deacylated derivate is low, 
even if the binding is specific. On the other hand, our data shows that the binding 
affinity of rHIgM22 for sulfatide can be modulated by the presence of other lipids 
suggesting a possible role of the membrane microenvironment in the recognition of the 
antigen by rHIgM22. In addition, rHIgM22 also reacts with phosphatidic acid, and with 
an unknown molecule present in lipid extracts from various sources, including CST 
knock-out mice brains, MGC, and isolated astrocytes and microglia. The exact identity 
of this antigen has yet to be confirmed but preliminary data suggests it might be a form 
of phosphatidylethanolamine with a free amino group and multiple hydroxylation in the 
fatty acid residues. Remarkably, this antigen is also present in the extracts from mixed 
glial cultures, which do not contain mature O4-positive oligodendrocytes, and also in 
isolated astrocytes and microglia suggesting that other glial cells in addition to 
oligodendrocytes might be important in the response to rHIgM22. All this suggests that 
not only sulfatide, but also other membrane lipids might play a role in the binding of 
rHIgM22 to oligodendrocytes and other cell types. Moreover, binding of rHIgM22 to 
intact cells might require a complex molecular arrangement, and, in particular, sulfatide 
might be part of the functional rHIgM22 antigen localized at the cell surface. 
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Glycosphingolipids 
 
Overview 
 
Eukaryotic cell membranes, whose basic role is that of a physical barrier between the 
extracellular milieu and the intracellular environment, are composed of a lipid bilayer. It 
is known that, in eukaryotic cells, there are three major classes of lipids: sterols, 
glycerolipids, and sphingolipids. All these classes have biochemical and biophysical 
properties that vary considerably and impact upon their function [11]. An accurate 
regulation of their composition is crucial for proper growth, division, and responses to 
environmental stimuli leading to a correct maintenance of the cellular homeostasis [12].  
The most abundant lipids in eukaryotic cell membranes are by far glycerophospholipids, 
a family of amphipathic molecules distributed asymmetrically across the plasma 
membrane. They do not only constitute the backbone of cellular membranes, but also 
provide the membrane with a suitable environment, fluidity, and ion permeability [13]. 
In neural membranes, it is possible to find three major classes of glycerophospholipids. 
These three, 1,2-diacyl glycerophospholipid, 1-alk-1-enyl-2-acyl glycerophospholipid 
or plasmalogen, and 1-alkyl-2-acyl glycerophospholipids, all have a glycerol backbone 
with a fatty acid, and a phosphobase (ethanolamine, inositol, choline, serine) [14].  
The most enriched glycerophospholipids in mammal tissues are 
phosphatidylethanolamine (PE) phosphatidylcholine (PC), phosphatidylserine (PS), and 
phosphatidylinositol (PI; PtdIns). Phosphatidic acid (PA; PtdOH) is also present in all 
cell membranes and has a role as precursor of all neural membrane 
glycerophospholipids. PA also acts as an intracellular second messenger regulating 
different signaling proteins [15, 16], including kinases, phosphatases, and also the 
transcription factor mTOR. Phosphatidic acid however is not the only 
glycerophospholipid able to act as a second messenger. For example, diacylglycerol 
(DAG), arachidonic acid, and phosphoinositides have also been implicated as 
messengers for Ca2+ homeostasis and protein phosphorylation [17-19]. 
Sphingolipids (SLs), first identified in the 19th century as major constituents of brain 
tissue by J. L. W. Thudichum [20], are minor amphipathic cell components, mainly 
residing in the outer layer of the plasma membrane with their hydrophilic head group 
facing out toward the extracellular milieu [21, 22]. They are universal components of 
eukaryotic cell membranes and are involved in various and important biological 
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functions [23]. Ceramide, the simplest sphingolipid, is the backbone of all complex 
sphingolipids which are characterized by the presence of a charged group linked to the 
hydroxylated group in position 1 of the sphingoid base [24], the most common base 
being sphingosine (2S,3R-D-erythro-2-amino-1,3-dihydroxy-octadec-4-ene), linked to a 
fatty acid through an amide bond. Homologous lipids with a different length of the 
carbon chain or with a saturated chain, sphinganine or 4-hydroxy-sphinganine, are 
present in cells in minor amount [25]. The polar head group, which defines the 
sphingolipid class, is a phosphate group in ceramide-1-phosphate, phosphorylcholine in 
sphingomyelin, monosaccharides in cerebrosides, and one or more sugar residues linked 
with a β-glycosidic bond in complex glycosphingolipids. The latter, are the most 
structurally diverse class of complex sphingolipids, and are normally classified as 
acidic, neutral or basic [11, 26]. They are ubiquitous components of mammalian cell 
membranes, but are particularly abundant in the nervous system where they are not 
merely structural components of the membranes, but also play other essential roles, 
especially in signaling. Of the simple SLs, ceramide, ceramide-1-phosphate, 
sphingosine and sphingosine-1-phosphate have been shown to be involved in several 
cellular events, like proliferation, motility, growth, differentiation, and apoptosis. 
Complex glycosphingolipids (GSLs) are involved in cell physiology by acting as 
antigens, mediators of cell adhesion, binding agents for growth factors, and as 
modulators of signal transduction [11]. Gangliosides, sialic acid-containing GSLs, have 
been shown to be involved in the development, differentiation, and function of nervous 
system in vertebrates [27]. Galactosylceramide (GalCer) and sulfatide, instead, are 
involved in the formation and maintenance of a myelin with a correct structure [28, 29], 
and deeply affect the survival, proliferation and differentiation of oligodendrocytes [30, 
31]. 
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Figure 1. Representatives of the major lipid classes of eukaryotic cell membranes.  
 
Glycosphingolipids biosynthesis, trafficking and degradation 
 
Over the past few decades, the biochemical pathways of glycosphingolipids metabolism 
and the intracellular sites of synthesis and degradation, respectively in the endoplasmic 
reticulum/Golgi apparatus and lysosomes, have been extensively characterized [32, 33]. 
Glycosphingolipids synthesis is set in motion by a sequence of three enzyme-catalyzed 
reactions that, at the cytosolic leaflet of the membranes of the endoplasmic reticulum 
(ER), lead to the formation of ceramide starting from L-Serine and palmitoyl-CoA [21]. 
Ceramide acts as precursor of at least five different products, namely ceramide-1-
phosphate, sphingosine, sphingomyelin (SM), glucosylceramide (GlcCer), and 
galactosylceramide (GalCer). After its synthesis, ceramide equilibrates to the luminal 
side of the ER where the ceramide galactosyltransferase (CGT) can convert it into 
galactosylceramide (GalCer), through the transfer of galactose from a UDP-galactose 
donor [34, 35]. GalCer then traffics through the Golgi apparatus where it can be sulfated 
or glycosylated [36, 37]. Ceramide is also transported from the ER to the Golgi complex 
via two alternative pathways. Ceramides with relatively short acyl chain length (C16-
C20) can be delivered by the ceramide transfer protein CERT to the trans-Golgi 
network where, after translocation across the membrane bilayer, it is used for the 
synthesis of SM, by transfer of phosphorylcholine from phosphatidylcholine to 
Phosphatidylethanolamine (PE)
Glucosylceramide
Cholesterol
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ceramide [38-40]. Alternatively, ceramide is transported from the ER to the cytosolic 
side of the cis-Golgi apparatus membrane through a CERT-independent mechanism [41, 
42]. There, the glucosylceramide synthase, a transmembrane glycosyl transferase, 
catalyzes the glycosylation of the primary hydroxyl group in ceramide using UDP-
glucose as a donor [43]. After its synthesis, GlcCer can either be transported across the 
Golgi complex via vescicular trafficking [44], or it can be picked up by the lipid 
transport protein FAPP2, which mediates the non-vescicular transport of GlcCer to the 
distal Golgi compartments [45, 46]. GalCer and GlcCer are precursors of the hundreds 
of known glycosphingolipids, which are formed via sequential transfer of sugars by 
galactosyltransferases, sialyltransferases, GalNAc transferases and GalCer 
sulfotransferases, all located in the Golgi apparatus [11, 47]. After GlcCer flips into the 
Golgi lumen, the addition of the next sugar residue leads to the formation of 
lactosylceramide (LacCer) that, once produced, cannot be translocated back to the 
cytosolic leaflet [44]. The final orientation of GSLs during their biosynthesis is 
consistent with their nearly exclusive appearance on the outer leaflet of the plasma 
membrane. While ceramide resides on intracellular organelles such as mitochondria, 
glycosphingolipids beyond GlcCer are not known to exist on membranes facing the 
cytoplasm [48, 49]. The biosynthesis of glycosphingolipids in the brain provides an 
example of how competing biosynthetic pathways can lead to glycan structural diversity 
[48]. Stepwise biosynthesis of GalCer and sulfatide occurs, in the brain, in 
oligodendrocytes, the myelinating cells of the central nervous system (CNS). Synthesis 
of GalCer and sulfatide, in the brain, is switched on at the onset of the terminal 
differentiation, and remains constant in mature oligodendrocytes [50]. Moreover, in rat 
brain, their synthesis is maximal at the developmental stage of most rapid myelination 
[51]. All this suggests that GalCer and sulfatide might represent not only structural 
components of the myelin sheath but also active players in myelin formation and 
maintenance [36]. Gangliosides, in contrast, are synthesized by all cells, with 
concentration of the different forms varying according to cell type. It is well known that 
during brain development there are marked changes in expression of glycoconjugates 
ranging from complex proteoglycans to gangliosides. The expression pattern shifts from 
simple gangliosides, like GM3 and GD3, to complex gangliosides, such as GM1, GD1a, 
GD1b, and GT1b, and this shift is mainly regulated by the differential expression and 
intracellular distribution of the enzymes required for the biosynthesis of these 
glycosphingolipids [52, 53]. Moreover, multiple glycosyltransferases can compete for 
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the same precursor. LacCer, for example, can act as a substrate for sialyltransferase I, 
which forms GM3, or for GalNAc transferase, which forms GA2 [54]. GM3, in turn, 
can be acted on by N-acetylgalactosaminyltransferase, forming GM2, or by 
sialyltransferase II, thereby forming GD3, the simplest “b-series” ganglioside [55, 56]. 
Due to the branch exclusivity, since sialyltransferases cannot convert a-series 
gangliosides to their b-series correspondent, the relative expression level of the final 
GSL products is determined by enzyme competition at each branch. The transfer of N-
acetylgalactosamine to a-, b-, and c-series gangliosides, converting GM3 into GM2, 
GD3 into GD2, or GT3 into GT2, is catalyzed by the same N-
acetylgalactosaminyltransferase. Likewise, the transfer of galactose to GM2 to form 
GM1, to GD2 to from GD1b, or to GT2 to form GT1c is accomplished by a single 
galactosyltransferase [57]. An additional level of regulation may occur via stable 
association of different glycosphingolipid glycosyltransferases into functional 
“multiglycosyltransferase” complexes. The enzymes involved are thought to act 
concertedly on the growing glycosphingolipid without releasing intermediate structures, 
ensuring progression to the preferred end product [58].  
While sphingolipid synthesis occurs in membranes of the secretory pathway, their 
catabolism occurs predominantly in endosomes and lysosomes. After internalization, 
GSL-rich membrane portions fuse with early endosomes, where the GSLs destined for 
degradation are sorted through the formation of multivescicular bodies which reach the 
lysosomes. Following the fusion, glycosphingolipids are exposed to lysosomal 
hydrolases and, in vivo, they are eventually broken down to their individual 
components, which are available for reuse [59, 60]. 
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Figure 2. Schematic biosynthetic pathway of glycosphingolipids. 
 
SMS-I
SMGalCerSulfatide
CGT
CST
GlcCer
LacCer
GlcT-I
GalT-I
GM3
GalNAc-T
GM2
GalT-II
GM1
SAT-IV
GD1a
SAT-V
GT1a
a-series
GA2
GalT-II
SAT-IV
SAT-V
GA1
GM1b
GD1c
GalNac-T
Asialo series
b-series
GD3
GalNAc-T
GD2
GalT-II
GD1b
SAT-IV
GT1b
SAT-V
GQ1b
SAT-II
SAT-I
Glc
Ceramide
Gal GalNAc
Neu5Ac
PO43-
Choline
SO3-
Introduction 
 
 
14 
 
Biological functions glycosphingolipids 
 
Studies on the role of glycosphingolipids using genetic, biophysical, biochemical and 
cell biology approaches led to establish that GSLs are essential for the proliferation, 
survival, and differentiation of eukaryotic cells within complex multicellular systems. 
Various studies involving the analysis of genetically engineered mice provided a 
general framework for the understanding of the roles of glycosphingolipids in mammals 
and their vital importance in the life of cells that are dealing with a multifaceted 
extracellular reality. These studies revealed that ablation of either GlcCer synthase or of 
B4GALT-V, responsible for the synthesis of LacCer, leads to embryonic lethality [61, 
62]. Moreover, mice lacking all ganglioside, as a result of the knockout of both 
GalNAcT and SAT-I genes, suffer severe lethality. These mice show enhanced cell 
apoptosis, perturbed axon-glia interactions and axonal degeneration [63], though, it still 
remains to be elucidated whether these phenotypes are the result of a functional 
deficiency or a consequence of the accumulation of substrate precursors.  
Glycosphingolipids are not randomly distributed along the membrane surface; 
moreover, they are highly segregated, together with cholesterol, in lipid domains with 
specialized signaling functions [64]. Within the cell, they are highly asymmetrically 
enriched in the external leaflet of plasma membranes, with the oligosaccharide chain 
protruding toward the extracellular space, where the sugar residues can engage cis and 
trans interactions with a wide variety of cell surface and extracellular molecules [65]. 
The local concentration of GSLs in the membrane affects these interactions. Direct 
lateral interactions (cis interactions) with plasma membrane proteins are strongly 
favored within a sphingolipid-enriched membrane domain [66], whereas in the case of 
trans interactions, it has been shown that recognition of lipid-bound oligosaccharides by 
soluble ligands (for example antibodies or toxins) or by complementary carbohydrates 
and by carbohydrate binding proteins (such as selectins or lectins) belonging to the 
interfacing membrane of adjacent cells is strongly affected by their degree of 
segregation (or dispersion) [67].  
This variety of interactions is reflected in the variety of roles of glycosphingolipids. 
GSLs, for example, act as receptors for bacteria and viruses. As a matter of fact, GM1 
acts as a receptor for cholera toxin B subunit [68, 69], Gb3 acts as a receptor for 
verotoxins [70, 71], whereas two of the surface proteins of influenza virus are aimed 
against the terminal Neu5Ac group on glycosphingolipids and glycoproteins of the 
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human host [72]. Some pieces of evidence also suggest a receptor role for 
glycosphingolipids in HIV infections. The HIV adhesin gp120, in fact, binds to several 
GSLs, including GalCer, sulfatide [73, 74], GM3, GD3 and also Gb3 [75, 76]. 
Glycosphingolipids also have a role in the modulation of the immune response. For 
example, the interdigitation of the acyl chains of long chain LacCer with the cytosolic 
leaflet of the bilayer, leading to Lyn kinase activation, has been strongly implicated in 
ligand activation of human neutrophils phagocytosis [77]. Moreover, LacCer has also 
been found to play a role in the induction of proinflammatory cytokines in both glial 
cells and neutrophils [78, 79], while gangliosides play a role in the modulation of the 
cytotoxicity of natural killer cells [80].  
Glycosphingolipids are also known to interact with growth factor receptors, to modulate 
cell growth, and, in many cases, to inhibit receptor-associated tyrosine kinases. An 
example of this is the interaction of ganglioside GM3 with the insulin receptor (IR). 
Accumulation of GM3 upon acquisition of insulin resistance leads not only to the 
displacement of IR from caveolin-1 complexes, required for  insulin signaling leading to 
the translocation of GLUT4 at the surface of normal adipocytes [81], but also to its 
sequestration in a complex with GM3 [82]. Another example is the epidermal growth 
factor receptor (EGFR) interaction with GM3. GM3 negatively regulates ligand-
stimulated autophosphorylation and dimerization of EGFR [83-85], and cross-talk of 
EGFR with integrin receptors [86] and PKCα [87], inhibiting EGFR-dependent cell 
proliferation and survival.  
Glycosphingolipids also play important roles in modulating several properties of tumor 
cells. Most tumor cells show altered glycosphingolipid patterns on their surface as well 
as abnormal sphingolipid signaling and increased glycosphingolipid biosynthesis, which 
together play a major role in tumor growth, angiogenesis, and metastasis [88, 89]. 
Glycosphingolipids are also known to play a role in the regulation of axonal growth. For 
example, gangliosides GD1a and GT1b, enriched in axonal rafts, act as MAG receptors 
in MAG-induced inhibition of axonal growth [90, 91].  
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Glial cells in the central nervous system 
 
Glial cells, neuroglia, or simply glia, in the mammalian adult central nervous system 
(CNS), comprise astrocytes, oligodendrocytes, and microglia. These cells, together, are 
by far the most abundant cells in the nervous system, comprising about 60-90% of all 
cells in the human brain [92, 93]. Rudolf Virchow, in 1856, named these cells glia, from 
the Greek word meaning glue, reflecting his view that these cells had the function to 
hold together the nervous system and, for a long time, they were thought only to support 
neurons passively. However, in the past few decades, evidence has shown that glia 
function as master regulators of the nervous system, providing valuable support in 
synaptic plasticity, axonal function, and acting as integral mediators of neuronal 
connectivity. Moreover, in addition to development and aging, these cells also play 
important roles in repair and remyelination in CNS disease [94-98]. 
 
Figure 3. The major types of glia interacting with a neuron.  
Adapted from Allen and Barres 2009 [92].  
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Oligodendrocytes  
 
Oligodendrocytes (OLs) are the myelinating cells of the CNS, and they are the last 
major neural phenotype to form during development. They arise from oligodendrocytes 
progenitor cells (OPCs), which can form either oligodendrocytes or astrocytes 
depending on the context [99, 100]. Once an OPC is committed to an oligodendroglial 
fate, it synthesizes large amounts of plasma membrane and extends multiple processes 
that individually wrap around axons generating a multilayered stack of membranes 
tightly attached at their cytosolic and external surfaces [1]. The thus formed myelin 
membrane provides electric insulation of axons and dictates the clustering of the sodium 
channels at the nodes of Ranvier and the organization of the node itself, allowing 
saltatory nerve conduction [2, 3]. In addition to these contributions to neuronal 
signaling, OLs also provide trophic support to neurons, and to long axons that may not 
receive adequate support from intra-axonal trafficking alone [97]. As such, 
oligodendrocytes are essential not only for the maintenance of neural transmission, but 
also of neurons themselves.  
Oligodendrocytes originate from neuroectodermal cells within the subventricular zone 
and, to be able to produce myelin, they go through highly regulated differentiation 
steps, that can be defined according to their migratory capacity, the increase in 
morphological complexity and the expression of specific markers, several of which are 
glycosphingolipids [101].  
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Figure 4. Oligodendrocyte maturation toward oligodendroglial lineage.  
Each stage is identifiable according to the increasing complexity in morphology, 
the ability to proliferate, migrate and differentiate, and the expression of specific 
antigens. Adapted from Barateiro et al, 2014 [101].  
 
During the main phase of myelination, oligodendrocytes generate about 5,000-50,000 
µm2 of myelin surface area per cell per day [102], and this is accomplished by a 
remarkable synthesis and transport of myelin lipids. Moreover, by the time myelination 
is completed, oligodendrocytes have synthesized about 40% of the total lipids in the 
human brain [103]. The myelin membrane has a unique composition, characterized by 
an high lipid content, ranging between 73 and 81% of its total dry weight [104]. 
Moreover, studies have shown that the ratio of protein to lipid is around 1 to 186 [105]. 
All the major lipid classes are found in myelin, like in other membranes, however 
myelin still has a remarkably characteristic composition. In fact, while in most cell 
membranes the molar ratio of cholesterol, phospholipids and glycosphingolipids is 
25:65:10, these ratios in myelin are in the range of 40:40:20 [106] which allows the 
close packing and tight organization of molecules within the membrane.  
The myelin membrane has a high level of cholesterol, at least 26% by weight [104, 107, 
108], which, in contrast with other cell types, is synthesized using mainly ketone bodies 
as precursors instead of glucose [109]. The high level of cholesterol not only is 
necessary for myelin growth and compaction, but also provides stability to this 
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membrane through the regulation of fluidity and permeability [108, 110]. Cholesterol is 
also necessary for correct myelin assembly, and the supply/synthesis of this molecule 
dictates this process, suggesting that upstream signaling systems which drive myelin 
biogenesis could be coupled to cholesterol metabolism [110].  
The myelin membrane also has a high amount of ethanolamine plasmalogens, whose 
levels correlate with the degree of myelination and reach the highest point between 30 
and 40 years of age, when myelination is complete [111, 112]. The structural features of 
these ethanolamine plasmalogens, like the perpendicular orientation of the sn-2 acyl 
chain instead of the bent orientation it has in phosphatidylethanolamine, favors a closer 
alignment of both acyl chains in plasmalogens, thus decreasing the fluidity of the 
membrane. Moreover, the absence of a carbonyl oxygen at the sn-1 position determines 
an increased hydrophilicity, resulting in stronger intermolecular hydrogen bonding 
between the head groups [113, 114]. Considering this, one of the function of the high 
level of plasmalogens in myelin could be to increase the packing density and with it the 
stability of the membrane. There is also evidence suggesting that plasmalogens could 
have a role in protecting unsaturated membrane lipids against oxidation by singlet 
oxygen [115] and in providing lipid mediators for inflammatory reactions [116]. 
Gangliosides, brain-enriched sialic acid-containing glycosphingolipids, increase not 
only in amounts but also in complexity as the brain develops [53]. The most prominent 
shift in gangliosides levels occurs in the late stages of fetal development and extends 
into the first two years of human development, a period that coincides with the most 
active phase of myelination, and, while only small amounts of gangliosides are present 
in myelin (~1% of total lipids), they represent a major fraction of the neuronal 
membrane [111]. It is known that gangliosides are able to interact with several growth 
factor tyrosine kinase receptors, thus regulating their activity [117]. For example, GM3 
binding to EGFR determines the inhibition of the receptor tyrosine kinase activity [83-
85], and several gangliosides inhibit the dimerization of PDGFR [118]. In addition, 
FGF-2 is able to interact with several gangliosides [119]. Specific gangliosides in the 
local environment could therefore modulate the activity of receptors such as PDGFR 
and FGFR, which are known to influence proliferation and differentiation of 
oligodendrocyte progenitors [102, 120]. Moreover, there is evidence that the addition of 
GM3, but not of other GM or GD gangliosides, determines an enhanced differentiation 
of OLs in culture [121]. Furthermore, two of the major axonal gangliosides, GD1a and 
GT1b, are involved in long term myelin stability via their trans interaction with the 
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myelin-associated glycoprotein (MAG), leading to MAG-induced inhibition of axon 
outgrowth [90, 91, 122]. Studies using mutants lacking a combination of gangliosides 
have further elucidated the role of gangliosides in myelination. Some mutations lead to 
the development of a severe phenotype, others do not affect myelination. For example, 
GD3 synthase null mice, lacking both b- and c-series gangliosides, do not exhibit 
demyelination in the brain [123]. In contrast, mice with disruption of the GM2/GD2 
synthase gene exhibit axonal degeneration, increased presence of unmyelinated, 
redundant myelin loops, disrupted paranodal junctions, and dysfunction of ion channels 
coupled with their erroneous localization [107, 124]. Taken together, these studies 
suggest a role of gangliosides in axon-glial interaction.  
Another distinguishing feature of myelin lipid composition, perhaps the most striking, is 
the enrichment in galactolipids. Galactosylceramide and 3-O-sulfogalactosylceramide 
(sulfatide), with long chain fatty acids, account for approximately 20% and 5% of 
myelin lipids respectively [30, 125]. Their biosynthesis involves two sequential steps. 
The enzyme UDP-galactose:ceramide galactosyltransferase (CGT), localized in the 
luminal side of the ER, catalyzes the transfer of a galactose from UDP-galactose to 
ceramide, thus forming GalCer [35]. A subpopulation of GalCer is then transported to 
the Golgi apparatus where the 3’-phosphoadenosine-5’-phosphosulfate:cerebroside 
sulfotransferase (CST) enzyme catalyzes the addition of the sulfate group, to obtain 
sulfatide [36, 125, 126].  
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Figure 5. Structure and biosynthetic pathway of sulfatide, the major 
sulfoglycolipid in the nervous system.  
3-O-sulfogalactosylceramide is highly heterogeneous in its fatty acid composition. 
The main fatty acids found in mature CNS myelin are long chain fatty acids (24:0 
and 24:1), including a significant amount of 2-hydroxylated fatty acids. Sulfatide 
synthesis requires the addition of galactose from UDP-galactose (UDP-Gal) to 
ceramide, catalyzed by the UDP-galactose:ceramide galactosyltransferase (CGT, 
EC 2.4.1.45, encoded by the ugt8 gene), and the subsequent addition of the sulfate 
group by the enzyme 3’-phosphoadenosine-5’-phosphosulfate:cerebroside 
sulfotransferase (CST, EC 2.8.2.11, encoded by the gal3st1 gene). 
 
 
Following their synthesis, both lipids are transported to the outer leaflet of the plasma 
membrane [107], and, although they are not myelin-specific lipids, their enrichment in 
myelin, which is common feature of both CNS and peripheral nervous system (PNS) 
across species, is much higher than in any other tissue [36]. The abundance of 
galactosylceramide and sulfatide has led to the hypothesis that they could be involved in 
myelin formation and stabilization, and in oligodendrocyte development [29]. 
Therefore, to gain a better understanding of the role of GalCer and sulfatide, genetically 
altered models have been established and analyzed. The animal models lacking the 
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enzymes responsible for the synthesis of GalCer and sulfatide, CGT knock-out and CST 
knock-out respectively, will be described in the following paragraphs. 
The CGT enzyme, responsible for the synthesis of galactosylceramide, is highly 
expressed in the actively myelinating CNS ad PNS [127, 128]. Even though the CGT 
knock-out mice cannot synthesize GalCer and sulfatide, they are still able to form 
myelin with an apparently normal structure, which could be due to a partial 
compensation of the loss of these galactolipids by synthesizing 2-hydroxylated 
glucosylceramide, usually not present in myelin. Moreover, in the myelin of this model, 
the level of hydroxy-fatty acid-containing sphingomyelin (HFA-SM) is also higher, 
which suggests that the α-hydroxy ceramide, normally destined for HFA-GalCer 
production, is most likely used for the synthesis of HFA-GlcCer and HFA-SM [29]. On 
the other hand, the deletion of glucosylceramide synthase in oligodendrocytes from 
CGT (-/-) mice did not alter the severity of the myelin defects, indicating that synthesis 
of GlcCer and GlcCer-based glycolipids is not essential for proper myelin formation, 
and suggesting that the levels of HFA-GlcCer are not sufficient to functionally 
compensate for the loss of GalCer in the CGT (-/-) model [129]. Nevertheless, even 
though this compensatory mechanism is not efficient enough, the CGT knock-out mice 
can form apparently normal myelin with a normal major dense and intraperiod line 
periodicity [130]. These animals, however, display a neuropathological phenotype, 
characterized by splaying of the hind limbs, tremors, and ataxic locomotion that 
progressively worsens, leading to death of most animals by the third month of age [29, 
131]. This phenotype is consistent with nerve conduction disruption despite the 
presence of compact myelin and, as a matter of fact, the action potential measured in the 
spinal cord of these mice is smaller and has a longer latency respect to wild type 
animals [29]. Moreover, while CGT (-/-) myelin is apparently normal, several 
ultrastructural abnormalities associated with myelination in the CNS have been 
identified. CNS myelin thickness is reduced, while nodal length is increased and lateral 
loops are widely spaced. The disorganization of the lateral loops suggests a disruption 
in the formation of the tight junctions, unsurprisingly since sulfatide is a prominent 
constituent of myelin tight junctions and the formation of these junctions may be 
dependent on the presence of sulfatide. These loops, loosely opposed to the axolemma, 
facilitate the entrance of cellular and non cellular material into the paranodal periaxonal 
space [132]. Additionally, in mutant mice, myelin sheaths also show a widespread, 
progressive vacuolation between the sheaths and the axolemma [29, 132]. Furthermore, 
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at least one-third of the myelin processes in CGT knock-out mice retains 
oligodendrocyte cytoplasm, indicating presence of immature myelin in regions that 
appear as structurally mature myelin, and profiles of compact myelin frequently show 
more than two oligodendrocytic loops in a single internodal segment [130, 133]. 
Despite the presence of all these anomalies in CNS myelin, PNS myelin appears normal 
suggesting that galactolipids, less abundant in the PNS, might not be as essential in the 
formation and maintenance of the PNS myelin sheath structure [130, 132, 134].  
The CGT (-/-) model, however, does not allow discrimination between the specific 
functions of GalCer and sulfatide, considering that in these mice they are both absent. 
To overcome this limitation, thus opening the way to the understanding of the specific 
functions of these two glycolipids, a new model, the CST knock-out mice, was 
developed [135]. The CST knock-out mice are completely devoid of sulfatide, whereas 
other glycolipids in the brain, galactosylceramide included, are not significantly altered 
[136]. CST-deficient mice are born healthy but, around 6 weeks of age, they start 
exhibiting hind limb weakness, followed by pronounced tremor and progressive ataxia. 
The phenotype of these mice is in fact similar to that of CGT knock-out mice, even 
though it is milder in terms of age of onset, life span and severity of symptoms which 
allows these mice to survive for more than one year [135]. CST knock-out mice produce 
compact myelin, even though its thickness is reduced, compared to that of wild type 
mice, and paranodal structure displays alterations similar to those of the CGT (-/-) mice. 
Whereas in young mice the myelin sheaths are rather stable, the node/paranode structure 
only moderately altered, and axon size is comparable to that of wild type mice, as they 
age these mice show nodal structure deterioration, myelin vacuolar degeneration and 
also reduction of axon caliber [137]. Furthermore, electron microscopy analysis of 
myelinated nerve fiber revealed disorganized termination of the lateral loops at the node 
of Ranvier [138]. CST (-/-) mice also exhibit a deterioration in the clustering of Na+ and 
K+ channels at the node [139]. In mutant mice Na+ channels concentrate in small 
regions, presumptive nodes of Ranvier, and the lengths of the clusters are occasionally 
higher than the ones present in the wild type mice. The K+ channels clusters instead 
accumulate in regions adjacent to the Na+ channels clusters in presumptive paranodal 
regions, whereas in normal CNS axons Na+ channels cluster at the node of Ranvier and 
the K+ channels concentrate in juxtaparanodal regions [139]. These alterations in 
localization and clustering of ion channels are present in both PNS and CNS and are 
accompanied by an altered distribution of axonal proteins such as Caspr, contactin and 
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NF155. Moreover, CST null mice show low levels of axonal paranodal Caspr and 
contactin, whereas paranodal NF155 is absent, even though its total cellular levels are 
unaltered, suggesting that sulfatide might play a role in the trafficking or stabilization of 
this protein at paranodal level [139-141]. 
The loss of GalCer and sulfatide affects the proliferation and survival rate of 
oligodendrocyte precursors. CGT knock-out mice show a significant increase in 
cellularity in the spinal cord [134], while CST (-/-) mice exhibit an increased number of 
oligodendrocytes, which mature earlier and in higher number [142]. In CGT (-/-) mice 
this increase seems to be due to an increased terminal differentiation [142], and this is 
supported by experiments showing that perturbation, either immunological or chemical, 
of GalCer and sulfatide leads to a dramatically altered maturation process in myelin 
forming cells [132]. This is in contrast with the observation that in CST (-/-) mice the 
increase in oligodendrocyte population seems to be determined by an increased 
proliferation and by a reduced apoptosis [143]. Interestingly, in CST null optic nerves 
the increase in cell numbers involves mostly mature oligodendrocytes, whereas 
astrocytes and microglia show no significant variation. In wild type mice the number of 
oligodendrocytes is strictly regulated by axons during development, and in fact the 
number of myelinating cells that survive seems to be precisely matched to the number 
and length of axons requiring myelination. In young CST knock-out mice, 
oligodendrocytes have fewer processes indicating that axons might need a greater 
number of oligodendrocytes to compensate for the fewer processes. However, it is still 
unknown if the same is true for adult CST null oligodendrocytes [144]. Taken together, 
the discrepancy in phenotype between CST- and CGT-null mice suggests that GalCer 
does not only act as a precursor for sulfatide synthesis, but also has a distinct function. 
GalCer appears to be primarily involved in myelin formation and maturation, while 
sulfatide contributes to the long term stability of myelin structure, in particular affecting 
the integrity and stability of the nodal and paranodal regions.  
GalCer and sulfatide, or more precisely, GalCer- and sulfatide-rich domains in the 
oligodendrocyte membrane also regulate the co-clustering and lateral distribution of 
several myelin proteins, thus affecting the proliferation, differentiation and survival of 
oligodendrocytes [31]. In the early stages of myelin formation, only a few typical 
myelin proteins are associated with lipid rafts. However, by the mid-myelination stage, 
when GalCer and sulfatide are synthesized at detectable levels, the 
myelin/oligodendrocyte glycoprotein (MOG) and the proteolipid protein (PLP) tend to 
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localize in lipid rafts, and subsequently, in the final stages of myelination MAG and 
myelin basic protein (MBP) are also translocated into lipid rafts[145-147]. In particular, 
sulfatide seems to be essential for the transport of PLP to myelin membranes, which is 
consistent with the observation that association of PLP is reduced in CGT (-/-) mice 
[148]. In addition, oligosaccharide-oligosaccharide trans interactions between GalCer 
and sulfatide present in the extracellular surfaces of the multilayered myelin membrane 
form a specialized “glycosynapse” which stabilizes the myelin sheath [149-152]. 
 
Figure 6. Glycolipid-enriched membrane domains in myelin. Glycolipid–
glycolipid and glycolipid–protein interactions play multiple roles in myelin 
formation, maintenance and functioning but also in axon-myelin stability and 
communication. GalCer and sulfatide on opposing surfaces of the myelin wrap 
interact with each other through trans carbohydrate–carbohydrate interactions 
forming a “glycosynapse” causing transmembrane signaling which results in 
clustering of membrane domains and loss of cytoskeleton integrity, leading to 
compaction and formation of mature myelin. On the other hand, GD1a and GT1b 
gangliosides, enriched in axonal lipid rafts, interact with MAG resulting in 
transmembrane signaling. MAG can also interact with Nogo-R1 (NgR1) which in 
turn interacts with signaling molecules p75/TROY and LINGO-1, leading to RhoA 
activation and axon outgrowth inhibition. Lateral interaction of GD1a and GT1b 
with p75 is important for the organization of NgR1 complex.  
Adapted from Aureli et al, 2015 [153]. 
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Astrocytes 
 
Astrocytes, or astroglia, are the most abundant and heterogeneous glial population in the 
central nervous system. In fact they outnumber neurons by over five fold [154]. 
Astrocytes have a plethora of functions, comprising roles as regulators of  CNS 
homeostasis, through control of ion, pH, and neurotransmitter metabolism, and roles in 
the development and maintenance of the BBB, and in synaptogenesis and myelination 
[155, 156]. They originate from the neural embryonic progenitor cells that line the 
lumen of embryonic neural tube, although they can also be formed indirectly via radial 
glia [157]. Though the heterogeneity of these cells is quite complex, the classification 
by Cajal, based on morphological differences, is still in use. Based on this classification, 
two main subtypes of astrocytes exist. Type 1 astrocytes, also named protoplasmic 
astrocytes, are localized in the gray matter where they ensheath blood vessels and 
synapses to promote blood brain barrier (BBB) and synapses functions [94]. Type 2 
astrocytes, defined fibrous astrocytes, are found in the white matter and have small cell 
bodies and processes aligned with myelinated fibers, which gives them an elongated 
morphology. They also contact the nodes of Ranvier and the blood vessels [94,155, 
158]. In addition to this, other morphologically distinct populations of astrocytes have 
been described [159]. Moreover, astrocytes can also be diverse in their ability, ranging 
from inactive (quiescent), which exist in the normal resting CNS, to active (reactive). 
Astrocytes become activated in response to all form of CNS insults (infection, trauma, 
ischemia, etc.) through a process defined as reactive astrogliosis [160].  
Recent evidence suggests a correlation between astroglial differentiation, during fetal 
cortical development, and lipid rafts, in particular phosphatidylglucoside-enriched lipid 
rafts (PGLRs). Phosphatidylglucoside (PtdGlc) is a glycoglycerolipid localized in the 
outer leaflet of the plasma membrane of several mammalian cell types, in particular in 
the brain, where it is highly expressed in the two neurogenic regions of the adult brain 
[161]. Its localization in the external leaflet of the membrane and its fatty acid 
composition, consisting solely of saturated fatty acyl chains, C18:0 at sn-1 and C20:0 at sn-
2 of the glycerol backbone, favor its segregation into PtdGlc enriched lipid rafts [162, 
163]. PGLRs are enriched in cells of astroglial lineage in developing mouse CNS [164] 
and they are potentially involved in astrogliogenesis, by physiologically coupling to 
EGFRs during late-embryonic stages of development. In fact, evidence shows that in 
multipotent neural progenitor cells treatment with DIM21, a mouse monoclonal that 
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recognizes preferentially PtdGlc, induced rapid recruitment and activation of EGFRs 
followed by the enhanced expression of the astrocyte marker GFAP (glial fibrillary 
acidic protein) [165]. 
Lipid rafts are also involved in the astrocytic inflammatory signaling. Recent evidence 
suggests a role of DJ-1 in the regulation of the inflammatory response to 
lipopolysaccharide (LPS) by modulating the lipid raft-dependent LPS/TLR4 pathway 
[166]. DJ-1 is a ubiquitous protein, highly expressed in both brain and peripheral 
tissues, that was initially described as an oncogene and whose mutations are associated 
with autosomal recessive forms and some sporadic cases of Parkinson disease [167]. 
Recent evidence suggests that DJ-1 is a multifunctional protein that has potent 
antioxidant properties and protects neurons against oxidative stress-induced cell injury 
[168]. Moreover, alterations in the expression levels of DJ-1 have been observed in 
various neurodegenerative diseases, including sporadic Parkinson disease, amyotrophic 
lateral sclerosis (ALS), and Alzheimer disease [169, 170]. Furthermore, recent findings 
suggest a role of DJ-1 in the pathogenesis of multiple sclerosis (MS), as DJ-1 mRNA 
and protein expression is enhanced in brain tissue of animal suffering from 
experimental autoimmune encephalomyelitis (EAE), a validated animal model for MS 
[168]. DJ-1, in the brain, is expressed in glial cells and neurons. Moreover, its 
expression is higher in astrocytes, where it associates with lipid rafts through 
palmitoylation, than in neurons [166]. LPS treatment and serum treatment of astrocytes 
increases DJ-1 association with lipid rafts, and, in turn, raft-associated DJ-1 seems to be 
able to regulate LPS signaling through the control of TLR4 endocytosis. As a matter of 
fact,  in DJ-1 knock-out astrocytes, TLR4 is retained on the plasma membrane 
following LPS stimulation, leading to an enhanced LPS/TLR4 signaling suggesting a 
role of DJ-1 in the regulation of the LPS/TLR4 pathway [166].  
In addition to roles of lipid rafts on the astrocytic inflammatory signaling, it has been 
shown that lipid rafts are involved in the signaling leading to ganglioside-induced 
astrocyte death [171] and in homeostatic roles of astrocytes such as glutamate clearance 
through EAAT2 modulation [172], and potassium buffering through the modulation of 
Kir4.1 [173]. 
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Microglia 
 
Microglial cells are widely regarded as the resident immune cells of the brain, 
constantly scanning through the microenvironment with their long protrusions, readily 
sensing alterations in tissue homeostasis and integrity [174]. These cells, representing 
around 10% of the total glial cells in the nervous tissue, are present ubiquitously in the 
CNS, even though they are more enriched in the grey matter than in the white matter 
[175]. Under non-pathological conditions, microglia cells are highly ramified. In the 
diseased brain however their morphology changes, becoming more amoeboid. Upon 
activation, microglia progressively changes aspect, increasing the size of the cell body, 
retracting protrusions, and expressing de novo or up-regulating distinct profiles of 
surface phenotypic antigens, leading to an increased motility and to the adoption of 
immune effectors functions. Moreover, reactive microglia produces pro-inflammatory 
mediators including nitric oxide, reactive oxygen species (ROS), tumor necrosis factor α 
(TNFα) and a wide variety of other inflammatory cytokines [176]. Under pathological 
conditions, microglial functions depend on the stimuli that led to their activation; 
moderate CNS damage elicits protection by microglia [177-179], while following an 
intensive acute activation (for example stroke) or chronic activation (typical of 
neurodegenerative diseases) these cells tend to become neurotoxic, thus impairing 
neuronal activity [180-182].  
The morphology and functions of microglia are highly affected by lipids, and changes 
in the composition of lipid rafts can lead to a decrease in the release of microparticles, 
which in turn leads to altered cell-cell communications [183]. Moreover, there is 
evidence showing that high levels of cholesterol increase the expression of pro-
inflammatory genes in microglia [184], while polyunsaturated fatty acids seem to have 
an anti inflammatory effect on these cells [185]. Sulfatide is also able to induce a rapid 
activation of microglia. As a matter of fact, sulfatide released at brain lesions sites, 
following myelin damage, determines not only an increase in the activation of 
intracellular signaling pathways, including MAPKs and inflammation-associated 
transcription factors, but also an increase in the production of inflammatory cytokines 
and chemokines [186].  
Lipid rafts, in these cells, are involved in several processes. For example, it has been 
shown that in microglial cells lipid rafts are involved in lysophosphatidylcholine 
(LysoPC) induction of ROS production, which leads to caspase-1 activation and to the 
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subsequent IL-1β processing. They are also involved in the internalization of α-
synuclein (α-syn), a key player in the pathogenesis of Parkinson’s disease (PD), through 
the interaction between ganglioside GM1, an unknown receptor, and the α-syn protein 
[187]. Moreover, caveolins, membrane adaptor proteins associated with lipid rafts, have 
been identified as structural and metabolic regulators of microglia. In particular, it has 
been observed that the switch between a resting phenotype and an immunoinflammatory 
one is associated with a switch in the caveolin isoform expression. When cells are in the 
inactive state, Caveolin-1 (Cav-1) levels are low and the protein is localized in 
cytoplasmic vescicles and at plasma membrane level. Caveolin-3 (Cav-3) instead is 
highly expressed and localizes in cellular processes and perinuclear regions. Upon 
microglia activation, concomitantly with the changes in cell morphology, Cav-3 
expression lowers, whereas Cav-1 expression increases. Cav-1 in these cells enhances 
mitochondrial function and acts as a negative regulator of microtubule stability, and, 
since lipid raft marker flotillin-1 levels increase alongside Cav-1 levels, it has been 
hypothesized that lipid rafts might be involved in the regulation of the morphology 
changes associated with the inactive-active state transition [188].  
In addition to contributing to the maintenance of the normal CNS functions and to their 
role as sensors of altered homeostatic conditions, microglia also regulates apoptosis and 
survival of developing neurons [189]. Moreover, microglia provides trophic support and 
promotes differentiation of astrocytes and oligodendrocytes. Furthermore, recent 
evidence suggests a possible role of microglia as multipotent stem cells able to 
differentiate into neurons, astrocytes and oligodendrocytes [190].  
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Myelin development, damage and repair  
 
Glial cells interaction in CNS (re)myelination and demyelination 
 
In the central nervous system, myelination is carried out by oligodendrocytes. The 
synthesis of myelin and the consequent ensheathment of axons by this multilamellar 
membrane restrict action potentials to short unmyelinated segments, namely the nodes 
of Ranvier. This provides the structural basis for saltatory action potential propagation, 
which in turn speeds up nerve conduction 10-20 times compared to non myelinated 
axons [191]. Myelin however is also important for axon maintenance and function 
[192]. Moreover, the cross talk between oligodendrocytes and axons is necessary to 
maintain metabolic function of axons, cytoskeletal arrangement, axonal transport, 
trophic support, and ion channel organization [97, 192-196].  
Whereas the early postnatal human brain is mostly non-myelinated, central nervous 
system myelination increases progressively in a defined temporal and topographic 
sequence within the first two decades of life [197]. During development, 
oligodendrocytes progenitor cells (OPCs), highly proliferative, motile, bipolar cells, are 
the main source for mature oligodendrocytes and myelin. These cells originate in 
sequential waves in specific regions of the ventral and dorsal neuroepithelium of the 
spinal cord and brain before migrating and dispersing into the CNS [198, 199]. The 
majority of these cells undergo a series of changes triggered by first contact with the 
axonal membrane and characterized by a rapid increase in morphological complexity 
and expansion of uncompacted myelin membrane, ultimately leading to their 
differentiation into myelinating oligodendrocytes [200]. A small pool of OPCs, 
characterized by the expression of the surface antigens platelet derived growth factor α 
receptor (PDGFαR) and neural/glial antigen 2 (NG2), instead, remains undifferentiated 
and quiescent in the adult CNS [199] where they are involved in myelin repair in the 
injured or diseased CNS [201]. A number of CNS diseases damage or destroy myelin 
and oligodendrocytes, leading to demyelination. This pathological process is typically a 
consequence of either a direct insult aimed at the oligodendrocytes, or of primary axonal 
loss. The first, commonly referred to as primary demyelination, can be further divided 
in two categories from a clinical point of view: genetic abnormalities affecting glia 
(leukodystrophies), and inflammatory damage to myelin and oligodendrocytes (multiple 
sclerosis being the most representative) [202]. Following the loss of the myelin sheath, 
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axons undergo several molecular reorganizations and physiological changes that 
ultimately result in axonal dysfunction, degeneration, and loss of sensory and motor 
function [203] and, regardless of causes or underlying mechanisms, the adult CNS has 
only a limited capability to repair damaged tissue. This limitation does not only involve 
neurons and their axons but also mature oligodendrocytes, unable to compensate for the 
myelin loss as they usually degenerate [204, 205]. However, demyelination often 
triggers a spontaneous myelin repair process, defined remyelination [202]. This process, 
mediated by OPCs that are recruited to differentiate and replace the lost 
oligodendrocytes [206], leads to myelin sheath restoration, reinstatement of saltatory 
conduction and functional recovery, and, ideally, it should recapitulate developmental 
myelination and tissue reconstruction should be complete. The myelin sheaths generated 
during this process however are thinner and exhibit shorter internodes than the 
developmental ones [207, 208]. On the other hand, recent data suggests that at late time 
points of recovery newly remyelinated fibers have comparable internode length and 
thickness compared to their developmental counterparts [209]. 
As previously stated, the remyelination process is mediated by OPCs. In particular, 
NG2/PDGFαR-expressing adult progenitors are recruited to lesion sites and differentiate 
into mature oligodendrocytes able to remyelinate axons, thus restoring nerve conduction 
[210]. The efficacy of this process however is compromised and limited by the 
inflammatory and activated milieu surrounding the demyelinated lesions [211]. In 
multiple sclerosis, for example, changes in the CNS microenvironment during the 
progression of the pathology cause OPCs to gradually lose their ability to respond to 
myelin damage, thus limiting their remyelination capacity [212]. All the steps of the 
remyelination process (OPC activation, recruitment, differentiation and myelination) are 
tightly regulated by a plethora of extrinsic and intrinsic factors acting either as 
activators or inhibitors [213, 214]. In response to injury, adult OPCs undergo a switch 
from a quiescent state to an active one, corresponding to a regenerative phenotype. 
During this activation step, the progenitor cells become responsive to growth factors, 
cytokines and chemokines, enhancing their proliferation and recruitment to the 
demyelinated area. Moreover, several genes involved in oligodendrocyte development 
and differentiation are upregulated [215-218]. Astrocytes and microglia, both activated 
by injury, are the main source of the factors that induce the rapid activation of OPCs 
during demyelination. Astrocytes, for example, secret several soluble factors implicated 
in enhancing myelination, including platelet derived growth factor (PDGF) and basic 
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fibroblast growth factor (FGF2) [200, 219-221], whereas microglia is able to induce 
chemotaxis of OPCs through the secretion of hepatocyte growth factor [222]. Following 
activation, OPCs, in addition to the ongoing proliferation, migrate to demyelinated 
areas. Concomitantly, macrophages and microglia begin the removal of the myelin 
debris, whose presence impairs remyelination [223, 224]. Astrocytes also play a role in 
this clearance, by inducing the recruitment of microglia to the lesion site, a process 
regulated by the chemokine CXCL10 [225]. Once OPCs reach the demyelinated area, 
they must differentiate into remyelinating oligodendrocytes. To do so, they need to 
establish contact with the demyelinated axon, synthesize the myelin membrane and 
subsequently form the myelin sheath, a process that presents many similarities with the 
developmental myelination.  
 
 
Figure 7. Phases of remyelination. Following demyelination, astrocytes and 
microglia activate, consequently leading to OPC activation. These activated OPC 
are then recruited and migrate toward the lesion area, while macrophages and 
microglia start to remove the myelin debris. In the final phase of remyelination, the 
recruited OPCs differentiate into mature oligodendrocytes, leading to the formation 
of a new myelin sheath. Adapted from Franklin et al, 2008 [202].  
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FGF and IGF, secreted respectively by astrocytes and microglia, play a role both in 
developmental myelination and in remyelination [226, 227]. However, differences 
between the regulation of development and regeneration of myelin do occur. OLIG1, for 
example, which is essential for developmental myelination, has a less redundant role 
during remyelination [228]. Another example is represented by the Notch signaling 
pathway, which is redundant during remyelination [229]. While remyelination can be 
quite efficient in experimental models, its efficiency remains generally low, leading to 
permanent deficits and dysfunctions. To a certain degree this decline is due to failure to 
the recruit OPC and to the failure of these cells to differentiate [202]. The underlying 
reasons for this are not completely understood but several pieces of evidence suggest 
the involvement of different factors, including age [230], gender [231], genetic 
background [232], and also the presence of a variety of differentiation inhibitors that 
affect the glial regeneration potential [214, 233]. 
 
Myelin damage in multiple sclerosis 
 
Several neurological diseases are characterized by loss of myelin sheath and destruction 
of oligodendrocytes. As previously stated, primary demyelination in the CNS can be 
caused by genetic abnormalities affecting glial cells. The diseases associated with this 
kind of abnormalities, though rare, usually present during childhood with generalized 
neurological symptoms. They can be divided into those due to defects of lysosomal 
function, like metachromatic leukodystrophy, those resulting from defects in astrocytes 
providing trophic support for myelinating cells, like Alexander’s disease, and those due 
to deficiencies or misfolding of myelin proteins which in turn lead to abnormal 
myelinogenesis, like hypomyelinating leukodystrophies [234]. Primary CNS 
demyelination can also be caused by inflammation damage. The diseases associated 
with this kind of damage, characterized by myelin loss that occurs on a background of 
inflammation, include pathologies such as multiple sclerosis (MS), Marburg disease, 
neuromyelitis optica (NMO), Balo’s concentric sclerosis, acute disseminated 
encephalomyelitis (ADEM) and its hyperacute variant, acute hemorrhagic 
leukoencephalitis (AHL) [235].  
Among these, MS has been considered the lead disease featuring demyelination as a 
result of the scientific effort invested into its description and of its high prevalence. 
Multiple sclerosis is the most common cause of non traumatic disability in young 
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people, with an onset usually between 20-40 years of age [236], affecting 2.5 million 
people throughout the world [237]. MS is characterized by inflammation, progressive 
demyelination and gliosis, axonal injury and loss. The pathological hallmarks of all the 
subtypes of this disease are focal areas, called plaques, of demyelination in the CNS, 
with surrounding inflammation and neurodegeneration [238, 239]. MS etiology 
however remains to be defined. Currently the most widely accepted hypothesis 
concerning MS pathogenesis is the autoimmune hypothesis. This hypothesis proposes 
autoimmune inflammation as the cause of demyelination, and auto-reactive leukocytes 
as disease initiators. The process begins when naïve myelin specific CD4+ T cells are 
primed in the lymph nodes by dendritic cells presenting either myelin or myelin cross-
reactive epitopes. These cells differentiate into Th17 cells following stimulation by 
interleukin 23 (IL-23), likely to play a central role in CNS autoimmunity [240, 241]. As 
these cells enter the CNS via subarachnoid space (SAS), together with activated 
macrophages, microglia and astrocytes, they secrete cytotoxic cytokines leading to 
demyelination [242-244]. A second hypothesis regarding MS onset is that the disease 
might be triggered by viral infection. This hypothesis does not exclude the autoimmune 
hypothesis, considering that virus could trigger the autoimmunity. Moreover, the viral 
infection might occur several years before the development of the MS lesions [245, 
246]. A large amount of evidence supporting these hypothesis however was obtained 
using the most frequently used MS animal model, experimental autoimmune 
encephalomyelitis (EAE) and, while there are similarities between EAE and MS, there 
are still major differences between the two [247]. Therefore, EAE, while useful and 
suitable to study CNS-immune relationships and to test drugs targeting the CNS, might 
not represent a complete model of MS and the autoimmune hypothesis remains 
unproven.  
There is, however, a third hypothesis, defined as the oligodendrogliopathy hypothesis, 
which is based on neuropathological studies on MS. Through histopathological 
examination of MS lesions Lucchinetti et al. defined four major immunopatterns, on the 
basis of specific myelin protein loss, plaque extent and topography, immunoglobulin 
deposition, oligodendrocyte destruction, and complement activation [235, 248], each 
possibly reflecting a different pathogenesis. Whereas in the first two types, type 1 (T 
cell-mediated autoimmune encephalomyelitis) and type 2 (T cell plus antibody-
mediated autoimmune encephalomyelitis), demyelinated lesions are associated with 
inflammation consisting mainly of T cells and macrophages, in the other two types, type 
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3 (primary oligodendroglial apoptosis) and type 4 (primary oligodendroglial dystrophy), 
oligodendroglial death is a prominent feature in active and inactive lesions. The four 
types of patterns identified by Lucchinetti were further analyzed first by Barnett and 
Prineas [249] and later on by Henderson [250]. These studies, based on a thorough 
analysis of  oligodendroglial apoptosis and inflammatory cell distribution in the various 
lesions, provided evidence suggesting that oligodendrocyte death and microglial 
activation are the initial event in MS lesion formation, followed by immune responses 
to scavenge dead myelin. Moreover, these immune responses seem to be permissive for 
oligodendroglial regeneration and remyelination, consistently with the observation that 
removal of myelin debris is necessary for remyelination [223]. The pathological 
heterogeneity observed in the four patterns is reflected in the clinical spectrum of MS. 
MS extends from an asymptomatic phase, of unknown duration starting at an unknown 
age, to clinically symptomatic phases commonly known as radiologically isolated 
syndrome, clinically isolated syndrome (CIS), single-attack MS (SAMS), relapsing–
remitting MS (RRMS), single-attack progressive MS (SAPMS), secondary progressive 
MS (SPMS), and primary progressive MS (PPMS) [235]. These different phases of MS 
are characterized by an interplay between different levels of inflammation-
demyelination, remyelination and axonal loss[251]. Moreover, remission of the disease 
symptoms in the initial stages is most likely due to a combination of resolution of 
inflammation, axonal plasticity, and remyelination. Furthermore, in early MS lesions 
remyelination is a frequent phenomenon while the majority of chronic MS lesions is 
characterized by limited remyelination [252]. The efficiency of this remyelination 
process seems to be influenced by factors such as anatomical localization, disease 
course, lesion size, and other patient dependent factors [252-255]. Astrocytes also seem 
to play a role. Following injury, these cells are activated and form a glial scar, 
composed of a dense network of hypertrophic cells, whose formation is crucial for 
restoring the blood brain barrier (BBB) normal function and integrity. In demyelinating 
conditions, however, the glial scar also represents a physical barrier hindering OPC 
entry into the demyelinated area to interact with neurons [192, 256-258]. Moreover, the 
scar also poses a biochemical obstacle for remyelination. The reactive astrocytes have 
marked changes in the expression levels of several molecules, including adhesion 
molecules, antigen presentation molecules, growth factors, receptor, cytokines, and 
protease inhibitors able to modify the composition of the extracellular matrix and to 
directly affect remyelination[259]. 
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Figure 8. Clinical course of multiple sclerosis. The majority of MS patients 
initially develop RRMS and, usually, during the remittance there is a spontaneous 
neurological recovery. Later, these patients progress to SPMS, and the functional 
recovery is abolished. The hallmark of MS lesions is inflammatory demyelination. 
Loss of mature oligodendrocytes is often associated with this demyelinating 
process. Adapted from Nakahara et al, 2012 [244]. 
 
Whether the immune response is the cause of the pathogenesis or simply a consequence 
of the oligodendroglial cell death, the failure of the immune system to discriminate 
myelin components from foreign antigens plays a critical role in the pathophysiology of 
MS. Several CNS myelin proteins, including MBP, PLP, MAG and MOG, have been 
described as targets for autoantibodies in MS [260-266]. Recent evidence however also 
suggests possible roles for myelin lipids in MS. In fact, in MS patients increased serum 
levels of glycolipids and anti glycolipid antibodies have been reported [267-271]. For 
example, it has been hypothesized that anti GD1a antibodies, increased in sera of MS 
patients, could have a role in the impairment of OPC maturation [272]. Moreover, it has 
been observed that MS patients exhibit an enhanced antibody response against 
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sulfatides [273, 274]. Furthermore, recent evidence has shown that increased levels of 
serum and CSF sulfatides are found in MS patients and in their healthy siblings, with 
stage-specific accumulation of different molecular species [275-277], suggesting that 
the presence of sulfatide in these biological fluids could represent a risk/prognostic 
factor for the onset and progression of MS.  
Studies have also shown how anti-sulfatide antibodies can interact with the surface of 
cultured oligodendrocytes and affect the lateral organization of sulfatide with myelin 
proteins with opposite consequences (demyelination versus stimulation of myelin 
formation), depending on the type of ECM protein prevalent in the culture environment 
[145]. Hence, these antibodies might play a role in the onset of the disease, but they 
might also represent an important immunological tool for the treatment of 
demyelinating diseases [278]. 
 
Therapeutic approaches and remyelination promotion 
 
The adult mammalian CNS is usually regarded as a regeneration incompetent organ, as 
opposed to the PNS, where axonal connections and myelin sheaths can be restored more 
easily [279]. The development of therapies aimed to promote remyelination within the 
demyelinated lesion in the CNS is an important therapeutic goal. In MS, naturally 
occurring remyelination is an overall inefficient process that fails to successfully 
counteract the accumulation of lasting axonal damage and increasing brain atrophy, thus 
resulting in motor and neurological deficits [4, 5]. Considering OPCs have been 
detected in chronic MS lesions [280], other determinants such as factors affecting 
migration and differentiation of these cells might be involved in the failure to 
remyelinate. Treatment able to modulate these factors could be clinically valuable. One 
of the FDA approved immunomodulatory drugs for MS, Fingolimod, is a sphingosine-
1-phosphate (S1P) receptor modulator able to control lymphocyte trafficking [281]. 
However, it was also found to modulate resident glial cells, including oligodendrocytes, 
and to increase remyelination efficiency [282-285]. It is however still unclear whether 
this remyelination-promoting effect is simply due to a modulation of the inflammatory 
microenvironment or if it is due to a direct modulation of oligodendrocytes. Currently 
two major approaches involving a more direct stimulation of the remyelination process 
are being tested in animal models of demyelination. The first approach involves the 
transplantation of cells capable of remyelination and is based on the evidence, gathered 
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from multiple studies, that transplanted glial cells myelinate in the CNS following their 
introduction in the developing CNS of rodents with myelin mutations or with toxin-
induced demyelination [286, 287]. This approach however has limitations. There is little 
benefit to be gained by transplanting OPCs into lesions that already contain abundant 
cells with the ability to generate new oligodendrocyte. In these lesions the environment 
is inhibiting differentiation and regeneration and it would likely do the same for the 
exogenous cells. Moreover, the method of delivery also represents a problem. In fact, 
while for focal lesions a single injection might be enough, for diffuse disease multiple 
injections at different sites, each carrying a risk of intracerebral hemorrhage, would be 
necessary [288]. The second approach being tested in animal models of demyelination 
involves the promotion of repair by the resident stem- and precursor-cell populations in 
the adult CNS, through the administration of growth, trophic, and neuroprotective 
factors [289]. This approach is based on the idea that if the mechanisms of 
remyelination can be understood, and non-redundant pathways described, the causes of 
remyelination failure and consequently possible therapeutic targets, will be identified. 
As discussed in previous sections, remyelination failure is likely associated with either 
failed recruitment or differentiation of OPCs. However, different and mutually 
exclusive biologies underlie these two phases or remyelination. For example, PDGF 
promotes OPCs proliferation and migration but there is also evidence showing its 
inhibitory effect in the final stages of differentiation when the myelin sheath is formed 
[290]. Therefore, therapies aimed to recruit OPCs might not promote remyelination in 
situations where the main problem is OPC differentiation, and vice versa [291, 292]. 
An alternative therapeutic approach is the use of CNS reactive antibodies to promote 
remyelination [6]. So far, all identified remyelination promoting antibodies have natural 
autoreactive antibodies (NAbs) features and are of the IgM isotype, with one exception. 
This exception is represented by the high affinity anti-LINGO IgG antibodies, which are 
able to promote remyelination but do not have NAb features. One of these anti-LINGO 
antibodies, BIIB033, a monoclonal antibody, is currently being tested for its efficiency 
as a remyelinating drug. Neutralization of LINGO-1, an axonal protein involved in the 
regulation of axonal growth and in OPC differentiation, has been found to promote 
remyelination in several animal models [293], and has fueled high expectations 
regarding its potential effect in MS. While a study investigating the effect of BIIB033 in 
optic neuritis (ClinicalTrial.gov: NCT01721161) has not reached its endpoint, a Phase II 
study in RRMS is still underway (ClinicalTrial.gov: NCT01864148).  
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Excluding the anti-LINGO IgGs, all remyelination promoting antibodies have NAbs 
features and are of the IgM isotype. These antibodies react to self antigens and, 
compared to conventional antibodies, they have a relatively low affinity. In addition, all 
remyelination promoting antibodies with identified antigens are polyreactive, as a result 
of their flexible antigen-binding site. Several of these monoclonal antibodies (mAbs) 
recognize not only protein antigens but also multiple sphingolipids. For example, the 
ganglioside-binding antibody A2B5 is able to recognize several GSLs due to their 
similar carbohydrate epitope [294, 295]. O4 recognizes sulfatide, seminolipid and also 
the unknown proligodendroblast antigen (POA) [296, 297], while HNK-1 targets MAG 
and also 3-sulfoglucuronyl paragloboside (SGPG) [298, 299]. All remyelination 
promoting IgMs produce a calcium influx in astrocytes, oligodendrocytes precursor 
cells, and immature oligodendrocytes [300]. The α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid glutamate receptor has been shown to mediate the calcium 
influx into oligodendrocytes (both OPC and immature OL), while this influx, after 
antibody stimulation, in astrocytes is mediated by inositol triphosphate-sensitive 
channels [300]. Another feature common to all remyelination promoting IgMs is their 
ability to access demyelinated lesions within the CNS. Direct evidence of this was 
obtained through a magnetic resonance imaging-based study, however, accumulation 
seems to occur only in models in which the BBB integrity is compromised, and not in 
animals without demyelination [7]. 
 
One of these remyelination promoting IgMs, recombinant human IgM22 (rHIgM22), is 
able to bind to myelin and to the surface of oligodendrocytes in vitro and has 
successfully completed a phase I clinical trial, aimed to evaluate safety, tolerability, 
pharmacokinetics and immunogenicity of a single intravenous dose of rHIgM22 in 
patients with MS (ClinicalTrial.gov: NCT01803867). In addition, a second phase I trial 
aimed to evaluate safety and tolerability in relapsing MS patients is now recruiting 
(ClinicalTrial.gov: NCT02398461). This antibody was first identified through the 
screening of human serum of a patient with Waldenström macroglobulinemia, a rare, 
low grade malignancy, characterized by the presence of IgM-secreting clonal cells in 
the bone marrow [301]. The serum of this patient was screened to identify antibodies 
able to bind to myelin, and, out of the six antibodies satisfying this criteria, two IgMs 
(sHIgM22 and sHIgM46) promoted significant remyelination in vivo [8]. sHIgM22, in 
particular, was able to bind to the surface of rat, mouse, and human oligodendrocytes [8, 
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278]. Further characterization of sHIgM22 led to the production of its recombinantly 
expressed version, rHIgM22 [302], which was found able to promote myelin repair in 
Theiler’s virus infection-induced (TMEV) and lysolecithin-demyelinated models of 
multiple sclerosis [303]. The actual target and mechanisms of rHIgM22 are still under 
investigation however several pieces of evidence suggest that the antigen recognized by 
this antibody might be a plasma membrane lipid, possibly sulfatide, and that lipid raft 
might be involved in the signaling associated with rHIgM22 remyelinating activity. 
This hypothesis is based on the observation that the well known anti-sulfatide antibody 
O4 and rHIgM22 have a similar binding pattern to CNS tissues [9], and that binding of 
rHIgM22 is abolished in CNS tissue sections from CST (-/-) mice [10]. Moreover, 
existing literature suggests that the binding target of rHIgM22 could be associated with 
detergent-resistant membranes (DRM)/lipid rafts and that rHIgM22 biological activity 
depends on lipid raft organization [9, 10]. rHIgM22 exerts its biological activity by 
inhibiting apoptotic signaling in OPCs and also by inhibiting the differentiation of these 
cells [9, 304]. The inhibition of the apoptotic signaling pathways is achieved via 
reduction of caspase-3 and caspase-9 cleavage and alteration of the caspase gene 
expressions in TMEV mice and in primary rat oligodendrocytes [9, 304], and this is 
dependent on calcium influx, through CNQX-sensitive AMPA channels [9]. Moreover, 
literature strongly suggests that rHIgM22 biological activity, responsible for its myelin-
repair promoting activity, could require a multimolecular complex organizing Lyn and 
the cell surface molecules integrin αvβ3 and PDGFαR [304, 305]. Taken together, these 
observations have led to hypothesize that rHIgM22, through its pentameric structure, 
could mediate the clustering of a lipid antigen and stabilize lipid rafts domains. 
Moreover, it could determine the reorganization of Lyn, integrin αvβ3 and PDGFαR to 
form a signaling complex which, in turn, promotes OPC survival and proliferation [10, 
304]. Signaling through this complex determines Lyn activation, and subsequent 
activation of the ERK 1/2 MAPK cascade, leading to the inhibition of caspase-3/9, to 
inhibition of OPCs differentiation and promotion of OPCs proliferation [305, 306].  
In isolated OPCs, PDGF is required for rHIgM22-mediated inhibition of apoptotic signaling 
and differentiation. PDGF is produced by neurons and astrocytes and stimulates OPC 
proliferation and promotes OPC survival both in vivo and in vitro. Indeed, IgM-mediated 
OPC proliferation is detectable only in cultures containing substantial amounts of 
astrocytes, microglia and OPCs (mixed glial cultures) but not in highly enriched OPC 
population [305]. 
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Figure 9. Proposed mechanism of action of rHIgM22. Binding of rHIgM22 to 
the surface of oligodendrocyte determines a reorganization of the membrane, 
favoring the interaction of Lyn, integrin αvβ3 and PDGFαR. IgM-stimulated 
activation of Lyn, with consequent activation of ERK 1/2 determines the inhibition 
of the apoptotic pathway and of OPC differentiation. Other factors (e.g. PDGF) 
might be required to promote the proliferation of these cells. Adapted from 
Watzlawik et al, 2013 [306]. 
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A number of CNS diseases damage or destroy myelin and oligodendrocytes, leading to 
demyelination. This pathological process is typically a consequence of either a direct 
insult aimed at the oligodendrocytes, or of primary axonal loss, and ultimately leads to 
the loss of the myelin sheath. Following demyelination in the central nervous system, a 
demyelinated axon has two possible fates. The normal response to demyelination, at 
least in most experimental models, is spontaneous remyelination, a process mediated by 
oligodendrocyte precursor cells. These cells are activated and recruited by the other 
glial cells in response to CNS injury and their proliferation and differentiation leads to 
the formation of new myelin sheaths, typically thinner and shorter than their 
developmental counterparts but nevertheless associated with functional recovery. 
However, even though in experimental models this process is efficient, remyelination is 
often inadequate in demyelinating diseases such as multiple sclerosis. If remyelination 
fails, the axon, devoid of its myelin sheath, undergoes several molecular reorganizations 
and physiological changes that ultimately result in axonal dysfunction, degeneration, 
and loss of sensory and motor function [203]. For this reason, therapies that increase the 
chances of the regenerative outcome of demyelination are keenly sought. 
One of the therapeutic approaches that is currently being developed to improve the 
regenerative outcome involves the use of CNS reactive antibodies to promote 
remyelination [6]. One of these antibodies, rHIgM22, is able to bind to myelin and to 
the surface of oligodendrocytes in vitro has successfully completed a phase I clinical 
trial for the treatment of MS (ClinicalTrial.gov: NCT01803867). Moreover, a second 
phase I trial aimed to evaluate safety and tolerability in relapsing MS patients is now 
recruiting (ClinicalTrial.gov: NCT02398461). This antibody is able to enter the CNS, 
accumulate at lesion site and promote remyelination in mouse models of chronical 
demyelination [7, 8]. The antigen recognized by this antibody and the molecular 
mechanism underlying the remyelinating activity of rHIgM22 however are yet to be 
elucidated. Evidence suggests that the binding target of rHIgM22 could be associated 
with plasma membrane lipid rafts, and that lipid rafts might be involved in the signaling 
associated with the biological activity of this antibody [9, 10]. Moreover, O4, an anti 
sulfatide antibody, and rHIgM22 have a similar binding pattern to CNS tissues [9], and 
binding of rHIgM22 is abolished in CNS tissue sections from CST knock-out mice [10], 
suggesting that the antigen recognized by rHIgM22 could be one or more CST-sulfated 
antigens present in myelin and on the surface of oligodendrocyte. 
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On the basis of these considerations, the aim of this study is to identify the molecular 
binding targets of rHIgM22, thus allowing a better understanding of the signaling 
mechanisms underlying the remyelination inducing activity of this antibody. The 
identification of the binding targets of this antibody, able to promote remyelination in 
validated mouse models of MS, and the characterization of their membrane 
microenvironment could significantly contribute to the reveal the signaling mechanisms 
underlying the biological activity of rHIgM22. This, in turn, would allow to gain a 
better knowledge regarding both the molecular mechanisms involved in the 
remyelination process, and the ones involved in MS aetiology thus allowing to define 
new potential therapeutic targets. 
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Materials  
 
Commercial chemicals were the purest available and, unless otherwise stated, were 
purchased from Sigma Aldrich Srl. 
Ca2+ and Mg2+-free HBSS, D-Glucose, BSA fraction V, HEPES, trypsin, sodium 
pyruvate, poly-D-lysine, poly-L-lysine, PBS, Na3VO4, KCl, NaOH, methanol, 
chloroform, polyisobuthylmethacrylate, O-phenylenediamine, H2O2, citric acid, 
Na2HPO4, and n-octyl-β-D-glucoside were purchased by Sigma Aldrich; 
penicillin/streptomycin, bovine fetal serum, DMEM high glucose, and glutamine from 
Euroclone Spa; MgSO4, CaCl2, and HPTLC plates from Merck; DNaseI from Roche 
Spa; acetic acid from Fluka; HCl from VWR International PBI Srl; HPA sensor chips 
and HBS-N buffer from GE Healthcare Srl. 
 
Chrompure Human IgM (#009-000-012) has been purchased from Jackson Immuno 
Research, Inc.; anti-MAG L-20 (#sc-9543) was purchased from Santa Cruz; HRP-
conjugated anti-human IgM μ-chain antibody (#31415) and HRP-conjugated anti-goat 
IgG (#31402) have been purchased from Thermo Fisher Scientific, Inc. 
The rHIgM22 antibody has been kindly provided from Acorda Therapeutics, Inc. 
(Ardsley, NY). 
 
Pure galactosylceramide (GalCer), sulfatides, and lyso PC were purchased from Avanti 
Polar Lipids; phosphatidylcholine (PC), DOPC, phosphatidylethanolamine (PE), 
phosphatidylinositol (PI), phosphatidylserine (PS), sphingomyelin (SM), and 
phosphatidic acid (PA) were purchased from Sigma Aldrich. Lysosulfatide was 
purchased from Matreya. Ceramide, gangliosides (GM3, GM2, GM1, GD3, GD1a, 
GD1b, GT1b), glucosylceramide (GlcCer), glucosylsphingosine (GlcSph), and 
lactosylceramide (LacCer) were synthesized or purified in our laboratories.  
PtdGlc and four structurally related lipids were kindly given us by Dr. Yoshio 
Hirabayashi (RIKEN Brain Science Institute, Laboratory for Molecular Membrane 
Neuroscience, Wako, Japan).  
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Animal specimens 
 
For the experiments reported in this thesis, the sources of animal specimens were: 
 
 wild type (WT) C57BL/6N mice and acid sphingomyelinase knock-out (ASM(-/-)) 
mutant C57BL/6N mice [307], used for brain lipid extraction, myelin purification 
and preparation of mixed glial cultures, cultured oligodendrocytes and astrocytes; 
 primary cultured rat oligodendrocytes positive for rHIgM22 staining (kindly 
prepared by Dr. Yana Zorina, Acorda Therapeutics, Ardsley, NY); 
 primary cultured rat microglia [183], kindly provided by Dr. Michela Matteoli, 
Department of Medical Biotechnology and Translational Medicine, University of 
Milano; 
 hemibrains from wild type and cerebroside sulfotransferase (CST) (+/-) and (-/-) 
mice [136], kindly provided by Dr. Xianlin Han, Sanford-Burnham Medical 
Research Institute, FL, USA.  
 
Cell culture 
 
Mixed glial cell (MGC) culture 
 
A primary mixed glial culture, composed of astrocytes, oligodendrocytes, and 
microglia, is obtained when newborn disaggregated cerebral brain cells from rat or 
mouse are plated at high cell density in serum-supplemented medium [305, 308]. In this 
culture model, neurons fail to survive and, after one week, mixed glial cell cultures are 
free of neurons, meningeal cells, and fibroblasts. MGC cultures were prepared 
according to Watzlawik et al [305]. Briefly, the hemispheres from P3 mice brains were 
minced with a surgical blade and then incubated for 30’ at 37°C in 0.05% trypsin in 
modified HBSS (Ca2+ and Mg2+ free HBSS containing 5 g/L D-glucose, 3 g/L BSA 
fraction V, 20 mM HEPES, 100 U/mL penicillin and 100 μg/mL streptomycin). 
Following the addition of MgSO4 and DNase I, the sample was centrifuged at 200 g at 
8°C for 5 minutes and resuspended in modified HBSS. The tissue was then further 
dissociated by trituration through a sterile flame narrowed glass pipette, centrifuged at 
200 g at 8°C for 10 minutes, resuspended in culture medium and plated on Petri dishes 
or T75 flasks coated with poly-D-lysine (25 μg/mL). 
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The cells were cultured in DMEM high glucose containing 10% heat inactivated FBS, 
100 U/mL penicillin, 100 μg/mL streptomycin, 1 mM sodium pyruvate, and 2 mM 
glutamine and the culture medium is changed every 3/4 days.  
With this protocol it is possible to obtain cultures with about 60-70% of astrocytes, 30-
40% of OPCs, and less than 3% of microglial cells. 
 
Glial cells (oligodendrocytes and astrocytes) isolation and differentiation 
 
Oligodendrocytes were harvested, through shaking procedure, from 8-10 days old 
mixed glial cell cultures, when the cell were mostly immature, containing progenitor 
cells and immature oligodendrocytes. Briefly, microglia and dead cells are removed 
with a 30 minute shake at 37°C, 150 rpm in a HT Infors minitron shaker (orbit size:25 
mm). After an 18-20 hour shaking to detach oligodendrocytes, the cell suspension was 
plated twice on untreated, non-TC, dishes to further remove microglia and astrocytes, 
before being centrifuged for 10 minutes at 8°C, 850 rpm. The surnatant was discarded 
and the pellet resuspended in OPC proliferative medium (DMEM:F12 1:1 containing 2 
mM glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 2% StemPro Neural 
Supplement, 10 ng/mL EGF, 10 ng/mL PDGF-AA, 10 ng/mL FGF-2). Media was 
replaced every 3/4 days and cells were carried using Accutase (Invitrogen). The cells 
obtained with this method are mostly immature oligodendrocytes.  
Mixed glial cell culture that underwent a shaking procedure to isolate oligodendrocytes 
precursors were used maximum three times. After the third time, the adherent layer was 
represented mostly by astrocytes, thus allowing to collect these cells. The collected cells 
were then stored at -80°C, before being lyophilized and subjected to lipid extraction. 
 
Lipid analysis 
 
Purification of myelin from mouse brain 
 
Myelin isolation was performed using an optimized version of the protocol described in 
[309]. Briefly, frozen brains from C57BL/6N wild type mice ranging from 2 to 4 
months of age were thawed at room temperature (RT) before removing the cerebellum 
and the meningeal membranes. 50 mg of tissue were suspended in 500 μL of 0.25 M 
sucrose in 10 mM Tris-HCl, pH 7.4 and Dounce homogenized (10 strokes, tight) before 
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being centrifuged at 500 g, 4°C for 10 minutes. The supernatant was collected and 
further centrifuged at 21000 g, 4°C for 10 minutes with Ultra-centrifuge Beckman TL-
100. The supernatant was discarded and the pellet was resuspended in 500 μL of 0.25 M 
sucrose in 10 mM Tris-HCl, pH 7.4 and then layered on top of 1250 μL of 0.88 M 
sucrose in 10 mM Tris-HCl, pH 7.4. After this, the samples were centrifuged at 21000 
g, 4°C for 10 minutes to separate the mitochondria from the myelin vesicles. In fact, 
myelin will float on the surface whereas the denser mitochondria will pellet at the 
bottom of the tube.  
The myelin vesicle layer was carefully recovered, resuspended in an equal volume of 
ice-cold water and then centrifuged at 21000 g, 4°C for 10 minutes. After discarding the 
supernatant, the pellet was resuspended in 500 μL of 0.25 M sucrose in 10 mM Tris-
HCl, pH 7.4, layered on top of 1250 μL of 0.88 M sucrose in 10 mM Tris-HCl, pH 7.4 
and centrifuged at 21000 g, 4°C for 10 minutes in order to separate myelin from 
membrane debris. The myelin layer was carefully recovered, resuspended in an equal 
volume of ice-cold water and then centrifuged at 21000 g, 4°C for 10 minutes. The 
supernatant was discarded and the pellet was resuspended in 120 μL of ice-cold water. 
Protein content was determined with DC protein assays (Bio-Rad). 
 
Lipid extraction 
 
Sample preparation 
Frozen brains and cerebella from C57BL/6N wild type mice ranging from 2 to 5 months 
of age, and frozen brains from cerebroside sulfotransferase (CST) (+/-) and (-/-) 3.5 
months old mice were thawed at room temperature (RT). Meninges were removed, the 
brains were minced with a surgical blade, resuspended in ice-cold water and subjected 
to sonication. The samples were then Dounce homogenized (10 strokes, tight) before 
being snap frozen and subsequently lyophilized.  
Frozen rHIgM22-positive rat oligodendrocytes from Acorda, and frozen rat microglia 
were thawed at RT, resuspended in ice-cold water, snap frozen and then lyophilized.  
Cultured mouse mixed glial cells, oligodendrocytes, and astrocytes were collected after 
washing the flasks and/or petri dishes twice with PBS containing 1 mM Na3VO4. The 
cells were scraped twice in PBS containing 1 mM Na3VO4 and centrifuged at 3000 rpm, 
4°C for 5 minutes. The supernatant was discarded, the pellet was snap frozen and stored 
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at -80°C. Frozen samples were then thawed at RT, resuspended in ice-cold water, snap 
frozen and lyophilized. 
 
Total lipid extraction, phase partitioning and alkali treatment 
Lipids from the lyophilized samples were extracted with chloroform/methanol/water 
20:10:1 (v/v/v) and subjected to a modified two-phase Folch’s partitioning to obtain the 
aqueous (Aq. Ph.) and the organic phases (Or. Ph.) [310]. Briefly, 1550 μL of the 
solvent system were added to the lyophilized samples. The samples were then mixed at 
1100 rpm, RT for 15 minutes and centrifuged at 13200 rpm, RT for 15 minutes. The 
supernatant was collected as Total lipid extract (TLE) and the extraction was repeated 
again twice by adding the 1550 μL of the solvent system to the pellets. The pellets were 
air dried and resuspended in 1N NaOH and incubated overnight at RT before being with 
water to 0.05N NaOH to allow the determination of the protein content with DC assay. 
Aliquots of the TLE were then subjected to phase partitioning adding either 20% of 
water by volume or 20% of 0.88% KCl in H2O by volume. The samples were then 
mixed at 1100 rpm, RT for 15 minutes and centrifuged at 13200 rpm, RT for 15 
minutes. The Aq. Ph. were recovered, and CH3OH:H2O 1:1 (v/v) or CH3OH: 0.88% 
KCl 1:1 (v/v) were added to the organic phase before mixing the samples at 1100 rpm, 
RT for 15 minutes and centrifuging at 13200 rpm, RT for 15 minutes. The new aqueous 
phases were recovered and united to the ones previously collected. The aqueous phases 
were dried under N2 flux, and resuspended in water before undergoing dialysis and 
lyophilization. The organic phases were dried under N2 flux and resupended in a known 
volume of cholesterol/methanol 2:1. Aliquots of the organic phases were then subjected 
to alkali treatment to remove glycerophospholipids [310]. 
 
Thin layer chromatography 
 
To determine endogenous lipid content, the various samples were analyzed by mono-
dimensional silica gel HPTLC using different solvent systems. The total lipid extracts 
were analyzed using chloroform/methanol/0.2% aqueous 60:35:8 (v/v/v) as a solvent 
system, the aqueous phases were analyzed with chloroform/methanol/0.2% aqueous 
CaCl2 50:42:11 (v/v/v), whereas the organic phases and the methanolyzed organic 
phases were analyzed using chloroform/methanol/water 110:40:6 (v/v/v). The organic 
phases were also subjected to HPTLC separation with chloroform/methanol/acetic 
acid/water 30:20:2:1 (v/v/v/v) to analyze the glycerophospholipid content.  
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Aqueous phases from wild type mouse brain were also analyzed by two-dimensional 
HPTLC [310] using chloroform/methanol/0.2% aqueous CaCl2 50:42:11 (v/v/v) as a 
solvent system for both of the separations. Between the first and second 
chromatographic run, the HPTLC was exposed to NH3 vapors for 3 hours at RT.  
After separation, lipids were detected either by spraying the TLC plates with different 
colorimetric reagents (anisaldehyde, aniline, Ehrlich’s reagent) or by TLC 
immunostaining. Identification of lipids after separation and chemical detection was 
assessed by co-migration with lipid standards.  
 
TLC immunostaining and dot blot 
 
rHIgM22 binding to individual purified lipids from commercial sources or to lipid 
extracts was assessed by TLC immunostaining following standard protocols [138, 139, 
311]. Briefly, after chromatographic separation (as described above) the TLC plates 
were coated three times with a polyisobuthylmethacrylate solution [310], and air dried 
for 1 hour before being immersed in blocking solution (3% BSA in PBS) for 1 hour. 
The plates were then incubated with rHIgM22 or isotype human IgM (Chrompure 
Human IgM; Jackson Immunoreasearch; negative control) at 5 μg/mL in 1% BSA in 
PBS or 5 μg/mL in 1% BSA in PBS (with/without 1% inactive goat serum) for 2 hours 
at RT or overnight at 4°C. After the incubation with the primary antibody, the plates 
were incubated with an HRP-conjugated anti-Human IgM μ-chain antibody for 1 hour, 
RT, and developed using o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate 
buffer pH 5.0.  
To allow a more quantitative evaluation, the binding of rHIgM22 to individual purified 
lipids was also assessed using a TLC dot blot system. In this case, different amounts of 
the lipids in analysis were applied as spots on silica gel plates. These plates were fixed 
with a polyisobuthylmethacrylate solution and the TLC immunostaining was carried out 
as described above. 
 
Surface Plasmon resonance 
 
The affinity of rHIgM22 for different purified lipids in supported lipid monolayers was 
assessed by SPR using a BIAcore 3000 analytical system (GE Healthcare, Uppsala, 
Sweden) with HPA sensor chips. Chips were incubated in the presence of DOPC 
liposomes containing different amounts of the target lipids. Liposomes containing the 
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target lipids were prepared following standard procedures. Briefly, different amounts of 
sulfatide (1 – 0.1 – 0.01 – 0.001 - 0.0005 μmol) in chloroform/methanol 2:1 were mixed 
with 1 μmol of DOPC, either alone or in presence of different amounts of a second lipid 
(cholesterol, GalCer, SM, lysosulfatide), and dried under N2 flux. The residue was then 
suspended in 200 μL HBS-N buffer (20 mM 4-(2-hydroxyethyl)-1-
piperizineethanesulfonic acid (HEPES) pH 7.4, 150 mM NaCl), mixed with a vortex 
mixer and sonicated for 15 minutes with a water bath sonicator. The solutions were then 
filtered using a 0.22 μm polyvinylidene difluoride (PVDF) syringe-driven filter unit. 
The sensor chip were pretreated with 40 mM n-octyl-β-D-glucoside and the liposome 
solutions were immobilized on the chip for 30 min at a flow rate of 2 μL/min, using 
HBS-N buffer without or with 1 mM CaCl2 and 1 mM MgSO4 as running buffer. The 
chip surface was then washed with 50 mM NaOH for 1 min at 5 μL/min, and blocked 
with 100 μg/ml bovine serum albumin (BSA) before proceeding with the analysis. For 
analysis, 5 μg/mL of rHIgM22 or control IgM were injected at a flow rate of 10 μL/min. 
Signals generated in a negative control cell without target lipid have been subtracted 
from the experimental values. Quantitative evaluation of the binding and dissociation 
reactions were performed using the software BIAevaluation version 3.1 [312]. 
 
Mass spectrometry 
 
Following the chromatographic separation of the aqueous phases, the area 
corresponding to the unidentified band was scraped. The scraped gel was subjected to 
lipid extraction, dialyzed and lyophilized. The lyophilized samples were then 
resuspended in chloroform and analyzed by ESI mass spectrometry in negative mode. 
The analyses of the compound were carried out using a ThermoQuest Finnigan LCQ 
Deca ion-trap mass spectrometer (Finnigan MAT, San Jose, CA) equipped with an 
electrospray ionization (ESI) ion source, an Xcalibur data system, and a TSP P4000 
quaternary pump. The conditions for MS analysis, in negative mode, were the 
following: sheath gas flow, 50 arbitrary units; spray voltage, 4 kV; capillary voltage, -
47 V; capillary temperature, 260°C; and fragmentation voltage (used for collision-
induced dissociation), 50%. 
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Protein analysis 
 
Protein quantification 
 
The protein quantification was performed through DC assay (Bio-Rad). The assay was 
performed in 96 well plates following the protocol supplied with the Bio-Rad DC assay 
kit. The samples were analyzed in triple, like the protein standard, bovine serum 
albumin (BSA), at different concentrations. 25 μL of reagent A and 200 μL of reagent 
B, both supplied with the kit, were added to each well. After 15 minutes of incubation, 
the absorbance at 750 nm was measured with the spectrophotometer. The samples 
reading were compared with the ones of the standard. The assay is linear between 1.5 
and 7.5 μg of protein amount. 
 
Electrophoresis and Western Blotting 
 
The samples were analyzed using electrophoresis on a polyacrilamide gel with 
denaturing conditions. The samples were resuspended in Laemmli buffer (1x: 62.5 mM 
Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 0.01% Bromophenol blue, 10% 
glycerol) and boiled for 5 minutes at 100°C before being analyzed. 
The electrophoresis run was performed using a Miniprotean II unit, produced by Bio-
Rad. To obtain optimal resolution, a stacking gel is polymerized on top of the resolving 
gel. A solution of 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3 was used as running 
buffer. The proteins were separated using 10% polyacrylamide gels. 
After electrophoresis separation, proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes, at 200 mA for 3 hours at 4°C with a wet blotting (Mini Transblot 
Biorad). The transfer buffer used is Blotting buffer 1x (25 mM Tris-HCl, 192 mM 
glycine, 15 % methanol, pH 8.0-8.5). 
After the transfer, the PVDF membranes were immunoblotted using either rHIgM22 
(lot 09-0052), Chrompure Human IgM (Jackson Immunoresearch, #009-000-012), or 
MAG (L-20; Santa Cruz, #sc-9543).Briefly, after the transfer the membrane was 
incubated in 5% milk in TBS-T 0.05% (1 mM Tris-HCl pH 8, 150 mM NaCl, 0.05% 
Tween) to block the aspecific binding sites of the membrane. The membrane was then 
washed three times with TBS-T 0.05% and incubated with a specific antibody (primary 
antibody) 1 hour at room temperature, depending on the antibody used. The primary 
antibody was diluted in a solution of TBS-T 0.05% containing 1% bovine serum 
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albumin (BSA). The membrane was washed again with TBS-T 0.05% for four times, to 
get rid of the antibody excess, before being incubated with the secondary antibody 
conjugated with horseradish peroxidase (HPR) at room temperature for 45 minutes. For 
membranes previously incubated with either rHIgM22 or Human IgM, an anti human 
IgM (Thermo, #31415) was used. For membranes incubated with MAG, an anti goat 
IgG (Thermo, #31402) was used. The membrane was then washed again for six times 
and the peroxidase activity was assessed through incubation with a non-radioactive light 
emitting substrate for the detection of immobilized specific antigens conjugated with 
horseradish peroxidase-linked antibodies (LiteAbLot Plus, Euroclone) for 2 minutes. 
The luminescent compound generated following the reaction can be detected through 
exposition to a photographic film (Kodak BioMax MR Film, Sigma-Aldrich). The data 
acquisition was performed using a GS-700 Imaging Densitometer. 
 
Statistical analysis 
 
Experiments were run in triplicate, unless otherwise stated. Data are expressed as mean 
value ± SD and were analyzed by one-way analysis of variance followed by Student-
Neuman-Keul’s test.  p-values are indicated in the legend of each figure. 
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Binding of rHIgM22 to purified lipids 
 
Binding to sulfatide 
 
The central nervous system (CNS) of vertebrates is characterized by the presence of 
myelin, a specialized multilamellar structure, produced by oligodendrocytes, which 
wraps around the axons and not only acts as an insulator, thus allowing saltatory 
transmission of the electric impulses, but also provides metabolic support to the axon 
itself [313]. The myelin membrane has a high lipid content and is enriched in 
glycolipids [107, 314]. In particular, galactosylceramide (GalCer) and sulfatide account, 
respectively, for about 20 and 5% of myelin lipids [30, 125]. It has been reported that 
rHIgM22 is able to bind to myelin and to the surface of oligodendrocytes in vitro [8, 10] 
and that it binds to CNS tissue sections with a pattern similar to that of O4, an anti-
sulfatide antibody [9], suggesting that sulfatide could be one of the antigen recognized 
by this remyelination-promoting antibody. 
Binding of rHIgM22 to different amounts of pure sulfatide from commercial sources 
(0.05 to 10 nmol) was assessed through TLC immunostaining following the protocol 
detailed in Materials and Methods. Different concentrations (0.5-5.0 g/mL) of the two 
primary antibodies, rHIgM22 and Human IgM (negative control), were used in the 
assay. The analysis revealed that rHIgM22 was able to bind pure sulfatide with a signal 
detectable from 0.5 nmol of the target lipid, and that the binding was proportional to the 
amount of sulfatide. The binding decreased if the concentration of the antibody was 
lowered, however the intensity of the signals was not quantitatively proportional to 
rHIgM22 concentration, at least below 2.5 µg/mL. Binding of the control Human IgM 
was also observed, however it was significantly lower than that of rHIgM22 for all 
experimental points, except for the IgM concentration of 0.5 µg/mL (Figure 10). 
On the basis of these results, surface plasmon resonance experiments were set up to 
allow a more quantitative analysis of rHIgM22 binding to sulfatide under experimental 
conditions where antigen presentation was closer to the one happening in a biological 
membrane, and also to verify the specificity of the binding. Binding of rHIgM22 to 
different amounts of sulfatide (0.0005 to 1 µmol), in monolayers of DOPC, was 
analyzed using sensor chips HPA and, as shown in Figure 11, it was significantly higher 
than the binding of the control IgM for all experimental points. Furthermore, the shape 
of the sensorgram was consistent with a specific binding for rHIgM22, and the binding 
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response increased with an increase of the amount of sulfatide present in the 
monolayers.  
Taking into account the values of maximum response and the prompt return to the 
baseline upon antibody removal, the DOPC:sulfatide 1:0.01 molar ratio was selected for 
further experiments aimed to analyze the binding response of rHIgM22 for monolayers 
containing different lipids which will be detailed in the following pages. Under the 
experimental conditions selected (DOPC:sulfatide 1:0.01 molar ratio), the binding 
response of rHIgM22 to sulfatide containing monolayers was consistent and highly 
reproducible (Figure 12).  
 
 
0.0
5
0.1
0
0.2
5
0.5
0
0.7
5
1.0
0
2.0
0
4.0
0
8.0
0
10
.00 0.0
5
0.1
0
0.2
5
0.5
0
0.7
5
1.0
0
2.0
0
4.0
0
8.0
0
10
.00
2.5 μg/mL
1.0 μg/mL
0.5 μg/mL
rHIgM22 Human IgM
5 μg/mL
nmol nmol
rHIgM22
0 2 4 6 8 10 12
0
5
10
15
20
25
   
 
 
nmol
OD
Human IgM
0 2 4 6 8 10 12
0
5
10
15
20
25
5 g/l 2.5 g/l 1 g/l0.5 g/l
nmol
OD
A
B
Materials and Methods 
 
 
58 
 
Figure 10. rHIgM22 binding to purified sulfatide in TLC immunostaining. 
rHIgM22 binding to different amounts of sulfatide (from 0.05 to 10 nmol) was 
assessed using TLC immunostaining. Briefly, after chromatographic separation 
(solvent system: CHCl3:CH3OH:H2O 110:40:6), TLC plates were fixed with a 
polyisobuthylmethacrylate solution, air dried and incubated with 3% BSA in PBS 
for 1 hour. The plates were then incubated with either rHIgM22 or Human IgM 
(negative control) in 1% BSA in PBS for 2 hours at room temperature (RT). 
Different concentrations of the two primary antibodies (5-2.5-1-0.5 μg/mL) were 
used in this assay. The plates were then incubated with a HRP-conjugated anti-
Human IgM μ-chain antibody for 1 hour at RT, and immunoreactive bands were 
revealed using o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer 
pH 5.0. Optical density of each band was calculated by densitometry and the 
results are shown in panel B. Data in panel B is expressed as mean ± SD of three 
independent experiments.  
Materials and Methods 
 
 
59 
 
 
Figure 11. rHIgM22 binding to purified sulfatide. DOPC (1 μmol) was mixed 
with different amounts of sulfatide (from 0.0005 μmol to 1 μmol) and dried. The 
lipid mixture was resuspended in HBS-N buffer, mixed vigorously and sonicated. 
The liposome solutions were immobilized on an HPA sensor chip. The surface was 
washed briefly with 50mM NaOH and blocked with 100 μg/mL BSA. For analysis, 
5 μg/mL rHIgM22 or Human IgM was injected. The binding of the two antibodies 
is represented as a sensorgram (Panel A) and also as maximum response (Panel B). 
Data in panel B are expressed as mean ± SD of three independent experiments; *, 
p<0.05 versus control.  
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Figure 12. Sensorgram of rHIgM22 binding to purified sulfatide. DOPC (1 
μmol) was mixed with sulfatide (0.01 μmol) and dried. The lipid mixture was 
resuspended in HBS-N buffer, mixed vigorously and sonicated. The liposome 
solutions were immobilized on an HPA sensor chip. The surface was washed 
briefly with 50mM NaOH and blocked with 100 μg/mL BSA. For analysis, 5 
μg/mL rHIgM22 or Human IgM was injected. Data are the mean + SD of four 
experiments; the dashed lines indicate the SD; * p<0.05 versus control.  
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Binding to lysosulfatide 
 
Lysosulfatide, the deacylated form of sulfatide, is present as a minor component in the 
normal CNS but its levels can be increased as a consequence of some pathological 
conditions, such as methachromatic leukodystrophy [315-317].  
Considering that rHIgM22 was able to recognize sulfatide in a specific manner, and 
considering that sulfatide and lysosulfatide bear the same 3-O-sulfo-galactose head 
group, the binding of rHIgM22 to these two lipids was compared. The binding to 
lysosulfatide was assessed using both TLC immunostaining and SPR experiments and, 
in both experimental settings, the antibody resulted able to bind to both lipids. In fact, 
rHIgM22, in TLC immunostaining assay, was able to recognize lysosulfatide even if the 
binding resulted 3-4 times weaker than that to sulfatide for equimolar amounts of the 
two lipids (Figure 13, panels A-B). The surface plasmon resonance experiments 
confirmed that the binding of rHIgM22 to the lyso lipid was specific, and also showed 
that the binding affinity for lysosulfatide is actually comparable with that to sulfatide 
(Figure 13, panel C). 
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Figure 13. rHIgM22 binding to purified sulfatide and lysosulfatide. rHIgM22 
binding to different amounts of sulfatide and lysosulfatide (from 0.05 to 10 nmol) 
was assessed using TLC immunostaining as shown in Panel A. Briefly, after 
chromatographic separation (solvent system: CHCl3:CH3OH:H2O 110:40:6), TLC 
plates were fixed with a polyisobuthylmethacrylate solution, air dried and 
incubated with 3% BSA in PBS for 1 hour. The plates were then incubated with 
either rHIgM22 or Human IgM at 5 μg/mL in 1% BSA in PBS for 2 hours at room 
temperature (RT). The plates were then incubated with a HRP-conjugated anti-
Human IgM μ-chain antibody for 1 hour at RT, and immunoreactive bands were 
revealed using o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer 
pH 5.0. Optical density of each band was calculated by densitometry and the 
results are shown in Panel B. Data in Panel B is expressed as mean ± SD of three 
independent experiments.  
The binding of rHIgM22 to sulfatide and lysosulfatide was also assessed using SPR 
(Panel C). DOPC (1 μmol) was mixed with either sulfatide (0.1 μmol) or 
lysosulfatide (0.1 or 0.5 μmol) and dried. The lipid mixture was resuspended in 
HBS-N buffer, mixed vigorously and sonicated. The liposome solutions were 
immobilized on an HPA sensor chip. The surface was washed briefly with 50mM 
NaOH and blocked with 100 μg/mL BSA. For analysis, 5 μg/mL rHIgM22 or 
Human IgM was injected. 
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Binding to glycerophospholipids 
 
From a quantitative point of view, the most significant lipids present in the myelin 
membrane, comprising 65% of the total lipid dry weight, are cholesterol, GalCer and 
phosphatidylethanolamine (PE), the latter consisting in large part of plasmalogens 
[318]. Considering the abundance of PE, and also of phosphatidylcholine (PC), in 
myelin, the binding of rHIgM22 to several glycerophospholipids was assessed through 
TLC immunostaining. As shown in Figure 14, while neither rHIgM22 nor the control 
IgM showed a significant binding to PC, the most abundant phospholipid in any 
biological membrane, they both weakly bound to PE, phosphatidylserine (PS) and 
phosphatidylinositol (PI), under experimental conditions similar to those used to assess 
binding to sulfatide, but there was no significant difference between the binding of the 
two antibodies. rHIgM22, on the other hand, showed a significant binding to 
phosphatidic acid (PA), which is not only a constituent of all cell membranes and an 
intermediate in the biosynthesis of triacylglycerols and other phospholipids, but is also 
suggested to act as an intracellular lipid second messenger [15]. In the case of PA, the 
control IgM gave no significant binding (Figure 14, panel A), suggesting that binding of 
rHIgM22 to this lipid might be specific. 
A recent paper by Nair S. et al [319], highlighted that immunoglobulins present in the 
sera of patients with monoclonal gammopathies are reactive against lyso PC. 
Considering this, binding to lyso PC was also assessed, although nor rHIgM22 nor 
control IgM showed a significant binding to this lysolipid.  
The binding of rHIgM22 to different amounts of phosphatidyl-β-D-glucoside (PtdGlc), 
a lipid characterized by a unique fatty acid composition and expressed at membrane 
level in several mammalian cell types but particularly enriched in the brain where it is 
localized to radial glia and nascent astrocytes [320], was also analyzed. The binding to 
other four uncharacterized lipids obtained from Dr. Hirabayashi (RIKEN, Wako, Japan), 
all structurally related to PtdGlc, was also analyzed however, neither rHIgM22 nor 
isotype IgM gave a significant binding for any of these lipids (Figure 15). 
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Figure 14. rHIgM22 binding to glycerophospholipids. rHIgM22 binding to 
different glycerophospholipids was assessed using TLC immunostaining as shown 
in Panel A and C. Briefly, after chromatographic separation (solvent system: 
CHCl3:CH3OH:CH3COOH:H2O 30:20:2:1), TLC plates were fixed with a 
polyisobuthylmethacrylate solution, air dried and incubated with 3% BSA in PBS 
for 1h. The plates were then incubated with either rHIgM22 or Human IgM 
(negative control) at 5 μg/mL in 1% BSA in PBS for 2 hours at room temperature 
(RT). The plates were then incubated with a HRP-conjugated anti-Human IgM μ-
chain antibody for 1 hour, RT, and developed using o-phenylenediamine 
(OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. For PE, optical density of 
each band was calculated by densitometry and the results are shown in Panel B. 
Data in Panel B is expressed as mean ± SD of three independent experiments.  
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Figure 15. rHIgM22 binding to PtdGlc and structurally related lipids. 
rHIgM22 binding to PtdGlc (panel A) and to four uncharacterized lipids 
structurally related to PtdGlc (panel B) was assessed using TLC immunostaining. 
Briefly, after chromatographic separation (solvent system: CHCl3:CH3OH:CaCl2 
50:42:11), TLC plates were fixed with a polyisobuthylmethacrylate solution, air 
dried and incubated with 3% BSA in PBS for 1h. The plates were then incubated 
with either rHIgM22 or Human IgM (negative control) at 5 μg/mL in 1% BSA in 
PBS overnight at 4°C. The plates were then incubated with a HRP-conjugated anti-
Human IgM μ-chain antibody for 1 hour, RT, and developed using o-
phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. 
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Binding to glycolipids 
 
As stated in previous sections, the myelin membrane has a high lipid content and is 
enriched in glycolipids [107, 314], the most abundant being galactosylceramide. 
Another major component of the myelin membrane is sphingomyelin (~5% of total 
lipids). Gangliosides, on the other hand, are minor components of the myelin membrane 
(<1% of total lipids) [105]. 
Binding of rHIgM22 to different glycolipids was assessed using TLC immunostaining. 
rHIgM22 was not able to bind significantly to galactosylceramide, lactosylceramide 
(LacCer), sphingomyelin (SM), nor to any of the gangliosides analyzed (Figure 16, 
panel A-B). A recent paper by Nair S. et al [319], reported that immunoglobulins 
present in the sera of patients with monoclonal gammopathies are reactive not only 
against lyso-PC, but also against glucosylsphingosine (GlcSph, lyso-GlcCer), so 
binding to glucosylsphingosine was assessed. Due to its role as a precursor for the 
synthesis of GlcSph, the binding to glucosylceramide (GlcCer) was also analyzed. Nor 
rHIgM22, nor control IgM, however, showed a significant binding to any of the 
aforementioned lipids (Figure 16, panel C). 
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Figure 16. rHIgM22 binding to glycolipids in TLC immunostaining. rHIgM22 
binding to different glycolipids was assessed using TLC immunostaining. Briefly, 
after chromatographic separation (solvent system: CHCl3:CH3OH:H2O 110:40:6, 
panel A; CHCl3:CH3OH:CaCl2 50:42:11, panel B), TLC plates were fixed with a 
polyisobuthylmethacrylate solution, air dried and incubated with 3% BSA in PBS 
for 1 hour. The plates were then incubated with either rHIgM22 or Human IgM 
(negative control) at 5 μg/mL in 1% BSA in PBS for 2 hours at room temperature 
(RT). Gangliosides were deposited at 3 μg each. The plates were then incubated 
with a HRP-conjugated anti-Human IgM μ-chain antibody for 1 hour at RT, and 
immunoreactive bands were revealed using o-phenylenediamine (OPD)/H2O2 in 
0.05 M citrate-phosphate buffer pH 5.0.  
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TLC immuno-dot blot 
 
The data obtained allowed to establish that rHIgM22 is able to bind to sulfatide and to 
lysosulfatide, in both TLC immunostaining assays and in surface plasmon resonance 
experiments. rHIgM22 however does not bind to other sphingolipids in vitro. On the 
other hand, this antibody shows a weak binding to some glycerophospholipids, 
especially PE. To quantitatively compare the binding of rHIgM22 and control IgM to 
sulfatide and PE in a different experimental setting, TLC-dot blot was set up. In these 
experiments, equimolar amounts of GalCer were used as background signals, since the 
previous experiments showed very weak or no binding for both rHIgM22 and control 
IgM to these lipids. As shown in Figure 17, for all the amounts of sulfatide and PE 
tested, the ratios of the binding signals between sulfatide and GalCer for rHIgM22 were 
always higher than those for control IgM, while the ratios of the binding signals 
between sulfatide and PE for rHIgM22 were always lower than those for control IgM, 
suggesting that rHIgM22 binding to sulfatide is specific, while rHIgM22 binding to PE 
is not. This hypothesis was further confirmed by TLC immunostaining experiments 
performed using stringent blocking conditions for non-specific binding, in particular by 
adding 1% heat-inactivated goat serum to the primary antibody (rHIgM22 or control 
IgM) solutions during incubation. In the presence of goat serum, binding of rHIgM22 to 
sulfatide was lower than in the absence of goat serum, however still detectable, while 
binding of rHIgM22 to PE, as well as binding control IgM to sulfatide or to PE was 
completely abolished (Figure 18).  
Using the TLC-dot blot approach, binding of rHIgM22 to sulfatide under different 
conditions of incubation of the primary antibody, was also assessed. In particular, the 
binding was analyzed modifying either time (2 hours vs overnight), temperature (room 
temperature vs 4°C) or stringency (presence or absence of 1% heat-inactivated goat 
serum in the antibody diluting solution). The data obtained suggests that a longer 
incubation time and a lower temperature might be enough to overcome the stability 
problems associated with the primary antibody (Figure 19). Regarding the addition of 
goat serum, these results, and the ones shown in Figure 18, suggest that it might be 
more useful in the analysis of lipid extracts than in the analysis of pure lipids. 
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Figure 17. rHIgM22 binding to purified PE, GalCer and sulfatide in TLC 
immuno-dot blot. rHIgM22 binding to different amounts of various purified lipids 
was assessed using TLC immuno-dot blot.  
Briefly, known amounts of pure lipids were deposited as spot on the TLC plates, 
without any chromatographic run. TLC plates were fixed with a 
polyisobuthylmethacrylate solution, air dried and incubated with 3% BSA in PBS 
for 1 hour. The plates were then incubated with either rHIgM22 or Human IgM 
(negative control) at 5 μg/mL in 1% BSA in PBS for 2 hours at room temperature 
(RT). The plates were then incubated with a HRP-conjugated anti-Human IgM μ-
chain antibody for 1 hour, RT, and developed using o-phenylenediamine 
(OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. Optical density of each 
spot was calculated by densitometry. The obtained density was divided by that of 
GalCer and the results are reported in panel C. Data are expressed as mean ± SD of 
three different experiments. *, p<0.05 versus control.  
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Figure 18. rHIgM22 binding to purified PE and sulfatide in presence of 1% 
heat-inactived goat serum in TLC immunostaining. rHIgM22 binding to 
different amounts of purified PE and sulfatide in presence or absence of 1% 
inactive goat serum was assessed using TLC immunostaining. Briefly, after 
chromatographic separation (solvent system: CHCl3:CH3OH:H2O 110:40:6), TLC 
plates were fixed with a polyisobuthylmethacrylate solution, air dried and 
incubated with 3% BSA in PBS for 1 hour. The plates were then incubated with 
either rHIgM22 or Human IgM (negative control) at 5 μg/mL in 1% BSA in PBS 
or 5 μg/mL in 1% BSA, 1% heat inactivated goat serum in PBS for 2 hours at room 
temperature (RT). The plates were then incubated with a HRP-conjugated anti-
Human IgM μ-chain antibody for 1 hour, RT, and developed using o-
phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0.  
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Figure 19. rHIgM22 binding to purified sulfatide in TLC immuno-dot blot. 
rHIgM22 binding to purified sulfatide was assessed using TLC immuno-dot blot. 
Briefly, known amounts of pure lipids were deposited as spot on the TLC plates, 
without any chromatographic run. TLC plates were fixed with a 
polyisobuthylmethacrylate solution, air dried and incubated with 3% BSA in PBS 
for 1 hour. The plates were then incubated with either rHIgM22 or Human IgM 
(negative control) at 5 μg/mL in 1% BSA in PBS ± 1% inactive goat serum either 
for 2 hours at room temperature (RT) or overnight at 4°C.  The plates were then 
incubated with a HRP-conjugated anti-Human IgM μ-chain antibody for 1 hour, 
RT, and developed using o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-
phosphate buffer pH 5.0. Optical density of each spot was calculated by 
densitometry. The results are reported in the panel B. Data in panel B is expressed 
as mean ± SD of three independent experiments.  
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Effect of different lipids on the binding of rHIgM22 to sulfatide containing 
monolayers 
 
Previous studies, performed using model membranes, have shown that antibody 
recognition of sulfatide is affected by the membrane lipid microenvironment. In fact, it 
has been seen that in a polyclonal anti-sulfatide serum fewer antibodies were able to 
recognize their own target in a sphingomyelin/cholesterol environment than in a 
phosphatidylcholine/cholesterol environment. Moreover, length and hydroxylation of 
fatty acid chain of PC or of SM seemed to restrict the recognition to higher affinity 
antibodies [321, 322]. Therefore, to verify whether the binding of rHIgM22 could be 
affected by lipid microenvironment, antibody binding to sulfatide containing 
monolayers was assessed through surface plasmon resonance experiments. In these 
experiments, monolayers were prepared by mixing a fixed amount of DOPC and of 
sulfatide, respectively 1 µmol and 0.01 µmol, with a third lipid using either molar ratios 
corresponding to those found in the myelin membrane or a 10 fold higher amount of the 
third lipid (Figure 20-21), reflecting the molar ratio expected for a lipid raft-like 
microenvironment.  
Binding analysis revealed that the binding response of rHIgM22 to sulfatide containing 
monolayers is reduced in the presence of either GalCer (0.66 or 0.066 µmol) or 
cholesterol (0.1 µmol), while the addition of SM (0.12 µmol) or of lysosulfatide (0.005 
– 0.01 – 0.1 – 0.5 µmol) to the monolayers determined a reduction of the binding. These 
finding suggest that the presence of different lipids, at a certain density might be 
required to allow an optimal recognition of the antigen by rHIgM22. 
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Figure 20. Effect of GalCer and Cholesterol on rHIgM22 binding to sulfatide. 
DOPC (1 μmol) and Sulfatide (0.01 μmol) were mixed with GalCer (0.66 μmol or 
0.066 μmol) (Panel A) or with Cholesterol (0.1 μmol) (Panel B) and dried. The 
lipid mixture was resuspended in HBS-N buffer, mixed vigorously and sonicated. 
The liposome solutions were immobilized on an HPA sensor chip. The surface was 
washed briefly with 50mM NaOH and blocked with 100 μg/mL BSA. For analysis, 
5 μg/mL rHIgM22 or Human IgM was injected.  
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Figure 21. Effect of SM and Lysosulfatide on rHIgM22 binding to sulfatide. 
DOPC (1 μmol) and Sulfatide (0.01 μmol) were mixed with SM (0.012 μmol) 
(Panel A) or with lysosulfatide (0.005 or 0.01 or 0.1 or 0.5 μmol) (Panel B) and 
dried. The lipid mixture was resuspended in HBS-N buffer, mixed vigorously and 
sonicated. The liposome solutions were immobilized on an HPA sensor chip. The 
surface was washed briefly with 50mM NaOH and blocked with 100 μg/mL BSA. 
For analysis, 5 μg/mL rHIgM22 or Human IgM was injected. 
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Binding of rHIgM22 to lipid extracts 
 
The experiments described in the previous sections allowed to set up the experimental 
conditions for the analysis of rHIgM22 binding to lipids after HPTLC separation using 
the TLC immunostaining procedure. The results obtained from the experiments on pure 
lipids suggest that rHIgM22 binds to pure sulfatide and, even if weaker, to lysosulfatide 
and to phosphatidic acid, whereas it does not show any significant binding to any other 
sphingolipid. On the other hand, a weak binding to glycerophospholipids was observed 
for both rHIgM22 and control IgM. The experiments that will be described in the 
following sections were aimed to analyze the binding of rHIgM22 to lipid mixtures 
obtained from a variety of relevant biological samples. Using standard lipid extraction 
and purification procedures, we have prepared a total lipid extract that has been further 
fractionated as described in Materials and Methods. The decision to prepare partially 
purified lipid mixtures from biological samples was taken considering that 
glycerophospholipids, that are present in higher amounts than sulfatide and 
sphingolipids in general in total lipid extracts, represent a significant source of 
interference in the TLC immunostaining procedure. Total lipid extracts (TLE), prepared 
in the experimental conditions used, contain all cellular lipids, including hydrophobic 
(cholesterol and triglycerides) and amphipathic lipids: glycerophospholipids and 
sphingolipids, neutral glycosphingolipids (GlcCer, LacCer, and in myelin and myelin 
producing cells, GalCer), and acidic sphingolipids (gangliosides, enriched in neurons, 
and sulfatide, enriched in myelin). Total lipid extracts were subjected to a two-phase 
Folch's partitioning (with minor modifications) and further purified using procedures 
aimed at obtaining lipid mixtures devoid of potentially interfering glycerophospholipids 
and enriched in sulfatide and other sphingolipids. Figures 22-27 show representative 
patterns obtained after chromatographic separation and chemical detection of the 
different lipid samples that we have prepared to be tested for the binding to rHIgM22 by 
immuno-TLC. The patterns are consistent with the known lipid composition of the 
biological samples.  
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Figure 22. TLC analysis of total lipid extracts and organic phases from mouse 
brain. Frozen brains from C57BL/6N mice (either wild type or ASMKO) ranging 
from 7 to 10 months of age were resuspended in ice-cold water and briefly 
subjected to sonication before being lyophilized. The samples were then subjected 
to lipid extraction with CHCl3:CH3OH:H2O 20:10:1 (v/v/v). Two aliquots of TLE 
were further subjected to a two-phase partitioning resulting in the separation of an 
aqueous phase containing gangliosides and in an organic phase containing all other 
lipids. One aliquot was partitioned adding 20% (volume) of water, the other adding 
20% of 0.88% aqueous KCl. Aliquots of the organic phases were then subjected to 
alkaline treatment to remove glycerophospholipids. For the analysis, we loaded 400 
g protein for each TLE, 350 g for O. Ph. and Met. O. Ph. Wt, and 250 g for O. 
Ph. and Met. O. Ph. ASMKO. The lipids were analyzed by HPTLC, using either 
CHCl3:CH3OH:H2O 110:40:6 (Panel A and B) or CHCl3:CH3OH:H2O 70:25:4 
(Panel C). The lipids were then revealed using colorimetric detection (Panel A: 
anisaldehyde; panel B: aniline; panel C: cresyl violet).  
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Figure 23. TLC analysis of total lipid extracts and aqueous phases from mouse 
brain. Frozen brains from C57BL/6N mice (either wild type or ASMKO) ranging 
from 7 to 10 months of age were resuspended in ice-cold water and briefly 
subjected to sonication before being lyophilized. The samples were then subjected 
to lipid extraction with CHCl3:CH3OH:H2O 20:10:1 (v/v/v). Two aliquots of TLE 
were further subjected to a two-phase partitioning resulting in the separation of an 
aqueous phase containing gangliosides and in an organic phase containing all other 
lipids. For the analysis, we loaded 400 g protein for each brain sample. The lipids 
were analyzed by HPTLC, using either CHCl3:CH3OH:CaCl2 0.2% 50:42:11 
(Panel A) or CHCl3:CH3OH:H2O 70:25:4 (Panel B). The lipids were then revealed 
using colorimetric detection (Panel A: anisaldehyde; panel B: cresyl violet). 
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Figure 24. TLC analysis of total lipid extracts, organic phases, and aqueous 
phases from mixed glial cells. Mixed glial cells at the 14th day of culture were 
collected in PBS and frozen. The frozen cells were then resuspended in water and 
lyophilized.Lyophilized samples were then subjected to lipid extraction with 
CHCl3:CH3OH:H2O 20:10:1 (v/v/v). Two aliquots of TLE were further subjected 
to a two-phase partitioning resulting in the separation of an aqueous phase 
containing gangliosides and in an organic phase containing all other lipids. One 
aliquot was partitioned adding 20% (volume) of water, the other adding 20% of 
0.88% aqueous KCl. Aliquots of the organic phases were then subjected to alkaline 
treatment to remove glycerophospholipids. The lipids were analyzed by HPTLC, 
using either CHCl3:CH3OH:CaCl2 0.2% 60:35:8 (Panel A), CHCl3:CH3OH:H2O 
110:40:6 (Panel B) or CHCl3:CH3OH:H2O 70:25:4 (Panel C). The lipids were then 
revealed using colorimetric detection (Panel A and B: anisaldehyde and aniline; 
panel C: Ehrlich). 
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Figure 25. TLC analysis of total lipid extracts, organic phases from rHIgM22 
positive oligodendrocytes. The frozen OPC were resuspended in water and 
lyophilized. Lyophilized samples were then subjected to lipid extraction with 
CHCl3:CH3OH:H2O 20:10:1 (v/v/v). Two aliquots of TLE were further subjected 
to a two-phase partitioning resulting in the separation of an aqueous phase 
containing gangliosides and in an organic phase containing all other lipids. One 
aliquot was partitioned adding 20% (volume) of water, the other adding 20% of 
0.88% aqueous KCl. Aliquots of the organic phase were then subjected to alkaline 
treatment to remove glycerophospholipids from the phase. For the analysis, we 
loaded 200 g protein for each sample. The lipids were analyzed by HPTLC, using 
either CHCl3:CH3OH:H2O 110:40:6 (Panel A and B) or CHCl3:CH3OH:H2O 
70:25:4 (Panel C). The lipids were then revealed using colorimetric detection 
(Panel A: anisaldehyde; panel B: aniline; panel C: cresyl violet). 
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Figure 26. TLC analysis of total lipid extracts and aqueous phases from 
rHIgM22 positive oligodendrocytes. The frozen OPC cells were resuspended in 
water and lyophilized. Lyophilized samples were then subjected to lipid extraction 
with CHCl3:CH3OH:H2O 20:10:1 (v/v/v). Two aliquots of TLE were further 
subjected to a two-phase partitioning resulting in the separation of an aqueous 
phase containing gangliosides and in an organic phase containing all other lipids. 
One aliquot was partitioned adding 20% (volume) of water, the other adding 20% 
of 0.88% aqueous KCl. For the analysis, we loaded 200 g protein for each 
sample. The lipids were analyzed by HPTLC, using either CHCl3:CH3OH:CaCl2 
0.2% 50:42:11 (Panel A, B, and C) or CHCl3:CH3OH:H2O 70:25:4 (Panel D). The 
lipids were then revealed using colorimetric detection (Panel A: anisaldehyde; 
panel B: aniline; panel C: Ehrlic's reagent; panel D: cresyl violet). 
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Figure 27. TLC analysis of total lipid extracts, organic phases from mouse 
myelin. Frozen myelin samples were resuspended in water and lyophilized. 
Lyophilized samples were then subjected to lipid extraction with 
CHCl3:CH3OH:H2O 20:10:1 (v/v/v). Two aliquots of TLE were further subjected 
to a two-phase partitioning resulting in the separation of an aqueous phase 
containing gangliosides and in an organic phase containing all other lipids. One 
aliquot was partitioned adding 20% (volume) of water, the other adding 20% of 
0.88% aqueous KCl. Aliquots of the organic phases were then subjected to alkaline 
treatment to remove glycerophospholipids. For the analysis, we loaded 50 g 
protein for each sample. The lipids were analyzed by HPTLC, using either 
CHCl3:CH3OH:H2O 110:40:6 (Panel A and B). The lipids were then revealed using 
colorimetric detection (Panel A: anisaldehyde; panel B: aniline). 
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Binding to total lipid extracts and organic phases 
 
Binding of rHIgM22 to various lipid samples was assessed using TLC immunostaining. 
Total lipid extracts and organic phases from different CNS cells and tissues (mixed glial 
cells, mice brain, oligodendrocytes, and myelin) were analyzed and, as shown in Figure 
28, the presence of glycerophospholipids in these samples strongly affected the binding 
of both rHIgM22 and control IgM. Both the antibodies, in fact, showed a binding to 
multiple bands with an intensity that was not proportional to the amount of the lipid 
samples. Therefore, even if the amount of sulfatide theoretically present in the samples 
was comparable to the amount detectable using pure sulfatide, the identification of 
signals corresponding to sulfatide was impossible. The removal of glycerophospholipids 
through alkali treatment of the organic phases proved to be a useful tool for the analysis 
of the binding of rHIgM22. When the binding of rHIgM22 to the methanolyzed organic 
phases, devoid of glycerophospholipids, was assessed through TLC immunostaining, a 
double band co-migrating with the sulfatide standard was detectable in all the samples 
analyzed (Figure 29). The control IgM also shows a weak reactivity for the same 
antigen however the binding of control IgM is significantly lower than that of rHIgM22 
in all the analyzed samples.  
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Figure 28. rHIgM22 binding to total lipid extracts and organic phases. Using 
TLC immunostaining we assessed rHIgM22 binding to different total lipid extracts 
(TLE) and organic phases (O.Ph.) obtained from different cells and tissues such as 
mixed glial cells, wild type mouse brain, ASMKO mouse brain, rHIgM22 positive 
OPC, and mouse myelin. For each extract and organic phase, either 150 μg protein 
(Panel A) or 75 μg protein (Panel B) were loaded on the TLC plates. The organic 
phases used for the analysis were obtained through partition in presence of 0.88% 
aqueous KCl. After chromatographic separation (solvent system: 
CHCl3:CH3OH:H2O 110:40:6), TLC plates were fixed with a 
polyisobuthylmethacrylate solution, air dried and incubated with 3% BSA in PBS 
for 1h. The plates were then incubated with either rHIgM22 or Human IgM 
(negative control) at 5 μg/mL in 1% BSA in PBS or 5 μg/mL in 1% BSA, 1% 
heath inactivated goat serum in PBS for 2 hours at room temperature (RT). The 
plates were then incubated with a HRP-conjugated anti-Human IgM μ-chain 
antibody for 1 hour, RT, and developed using o-phenylenediamine (OPD)/H2O2 in 
0.05 M citrate-phosphate buffer pH 5.0.  
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Figure 29. rHIgM22 binding to methanolyzed organic phases in TLC 
immunostaining. Using TLC immunostaining we assessed rHIgM22 binding to 
methanolyzed organic phases (O.Ph.Met) obtained from different tissues such as 
wild type mouse brain, ASMKO mouse brain, rHIgM22 positive OPC, and mouse 
myelin. For each methanolyzed organic phase amounts equivalent to 150 μg 
protein were loaded on the plate, while for each pure lipid standard 3 nmol were 
loaded. The methanolyzed organic phases used for the analysis were obtained from 
organic phases partitioned in presence of 0.88% aqueous KCl. After 
chromatographic separation (solvent system: CHCl3:CH3OH:H2O 110:40:6), TLC 
plates were fixed with a polyisobuthylmethacrylate solution, air dried and 
incubated with 3% BSA in PBS for 1h. The plates were then incubated with either 
rHIgM22 or Human IgM (negative control) at 5 μg/mL in 1% BSA, 1% heath 
inactivated goat serum in PBS for 2 hours at room temperature (RT).  
The plates were then incubated with a HRP-conjugated anti-Human IgM μ-chain 
antibody for 1 hour, RT, and developed using o-phenylenediamine (OPD)/H2O2 in 
0.05 M citrate-phosphate buffer pH 5.0. 
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Binding to aqueous phases 
 
Aqueous phases obtained partitioning in presence of water, which contained a 
significant amount of sulfatide, were also analyzed using TLC immunostaining (Figure 
30). rHIgM22-immunoreactive bands co-migrating with the sulfatide standard were 
observed in samples from mice brain, rHIgM22 positive oligodendrocytes, and myelin. 
Interestingly, in all the samples the presence of a second rHIgM22 immunoreactive 
antigen, migrating below sulfatide, was observed. The position of these bands 
corresponds to that of the pure lysosulfatide standard, however literature suggests that 
lysosulfatide levels are quite low in non-pathological nervous tissue. Moreover, the 
experiments performed on pure lysosulfatide indicated that the binding of rHIgM22, at 
least in these experimental settings, should be weaker than the one to sulfatide. 
Nevertheless, the signal corresponding to these bands resulted quite strong, suggesting 
that rHIgM22 might recognize this antigen with a stronger affinity than that to sulfatide. 
Remarkably, this unidentified rHIgM22 positive antigen is also present in the aqueous 
phases obtained from samples that do not contain any sulfatide. In fact, it is present in 
aqueous phases from hemibrains harvested from mice that are knock-out for the 
cerebroside sulfotransferase (CST) enzyme, responsible for the synthesis of sulfatide. 
Moreover, the antigen can be detected in samples from mixed glial cell cultures, which 
do not contain sulfatide, consistently with their lack of O4 positive oligodendrocytes, 
and in samples from rat microglia and mice astrocytes (Figure 31). The presence of 
these bands in samples devoid of mature oligodendrocytes suggests a possible role of 
other glial cells in the biological response mediated by rHIgM22.  
The presence of the second immunoreactive band also seems to be affected by the 
protocol of partitioning chosen. In fact, in samples partitioned by adding 0.88% KCl 
instead of water, following immunostaining with rHIgM22, the intensity of the 
unknown band is reduced as shown in Figure 32.  
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Figure 30. rHIgM22 binding to aqueous phases in TLC immunostaining. 
Using TLC immunostaining we assessed rHIgM22 binding to aqueous phases 
(A.Ph.A, obtained by partitioning the TLE with water) obtained from different cells 
and tissues such as mixed glial cells, wild type mouse brain and hemibrain, 
ASMKO mouse brain, rHIgM22 positive OPC, mouse myelin, CST (+/-) and (-/-) 
hemibrain, and rat microglia. For each A.Ph. amounts equivalent to 150 μg protein 
were loaded on the plate, while for each pure lipid 3 nmol were loaded. After 
chromatographic separation (solvent system: CHCl3:CH3OH:CaCl2 50:42:11), TLC 
plates were fixed with a polyisobuthylmethacrylate solution, air dried and 
incubated with 3% BSA in PBS for 1h. The plates were then incubated with either 
rHIgM22 or Human IgM (negative control) at 5 μg/mL in 1% BSA, 1% heath 
inactivated goat serum in PBS for 2 hours at room temperature (RT). The plates 
were then incubated with a HRP-conjugated anti-Human IgM μ-chain antibody for 
1 hour, RT, and developed using o-phenylenediamine (OPD)/H2O2 in 0.05 M 
citrate-phosphate buffer pH 5.0. 
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Figure 31. rHIgM22 binding to aqueous phases from astrocytes. Using TLC 
immunostaining we assessed rHIgM22 binding to aqueous phases (A.Ph.A, 
obtained by partitioning the TLE with water) obtained from wild type mouse 
hemibrain, and astrocytes. For each A.Ph. amounts equivalent to 150 μg protein 
were loaded on the plate, while for each pure lipid 3 nmol were loaded. After 
chromatographic separation (solvent system: CHCl3:CH3OH:CaCl2 50:42:11), TLC 
plates were fixed with a polyisobuthylmethacrylate solution, air dried and 
incubated with 3% BSA in PBS for 1 hour. The plates were then incubated with 
either rHIgM22 or Human IgM (negative control) at 5 μg/mL in 1% BSA in PBS 
overnight at 4°C. The plates were then incubated with a HRP-conjugated anti-
Human IgM μ-chain antibody for 1 hour, RT, and developed using o-
phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. 
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Figure 32. rHIgM22 binding to aqueous phases in TLC immunostaining. 
Using TLC immunostaining we assessed rHIgM22 binding to aqueous phases 
(A.Ph.A, obtained by partitioning the TLE with water; A. Ph. B, obtained by 
partitioning TLE with 0.88% aqueous KCl) obtained from wild type mouse 
hemibrain, CST (+/-) and (-/-) hemibrain. For each A.Ph. amounts equivalent to 
150 μg protein were loaded on the plate, while for each pure lipid 3 nmol were 
loaded. After chromatographic separation (solvent system: CHCl3:CH3OH:CaCl2 
50:42:11), TLC plates were fixed with a polyisobuthylmethacrylate solution, air 
dried and incubated with 3% BSA in PBS for 1 hour. The plates were then 
incubated with either rHIgM22 or Human IgM (negative control) at 5 μg/mL in 1% 
BSA in PBS for 2 hours at room temperature (RT).  The plates were then incubated 
with a HRP-conjugated anti-Human IgM μ-chain antibody for 1 hour, RT, and 
developed using o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate 
buffer pH 5.0.  
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Characterization of rHIgM22 immunoreactive unknown antigen 
 
Colorimetric assays 
 
To identify the second rHIgM22 immunoreactive antigen, aqueous phases obtained 
from wild type mice hemibrains, as well as ones obtained from CST (+/-) and CST (-/-) 
mice hemibrains have been analyzed with different colorimetric reagents after 
chromatographic run. As shown in Figure 33, the unknown bands were positive for 
anisaldehyde, a reagent for the non-selective detection of lipids, and they were also 
positive for ninidrine and for the phosphorous spray [323], reagents selective, 
respectively, for free NH2 groups-containing lipids and for phosphate-containing lipids. 
In the case of aniline, a reagent for the selective detection of glycolipids, there was a 
reactivity but the presence of multiple bands with non characteristic color in that area 
did not allow to conclusively say whether or not the unknown antigen could be a 
glycolipid.  
Aqueous phases obtained from wild type mice hemibrains were also analyzed through 
two-dimensional TLC. To verify if the unknown antigen is an alkali-sensitive lipid, 
which are relatively common in brain lipid extracts, the plates, in some experiments, 
were exposed to ammonia vapors between the first and the second chromatographic 
separations (Figure 34). The binding of rHIgM22 to the antigen after two-dimensional 
separation, with or without alkali treatment, was assessed through TLC immunostaining 
(Figure 35-36). As shown in Figure 36, rHIgM22 is able to recognize the second 
immunoreactive band, which is modified by the alkali treatment (as indicated by its 
altered migration in the second run after exposure to ammonia vapors), even after a 3 
hour treatment with ammonia vapors, suggesting that while the antigen is modified by 
the treatment, this is not altering the motif recognized by the antibody.  
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Figure 33. Characterization of unknown rHIgM22 positive antigen in aqueous 
phases from mouse hemibrain. Aqueous phases from hemibrains from wild type, 
CST (+/-) and CST (-/-) mice have been analyzed. For each extract, amounts 
equivalent to 150 μg protein were loaded. Briefly, after separation with 
CHCl3:CH3OH: 0.2%CaCl2 in H2O 50:42:11, the plates were sprayed with 
appropriate chemical reagents. Binding of rHIgM22 to the unknown antigen was 
assessed using TLC immunostaining. Briefly, after chromatographic running, TLC 
plates were fixed with a polyisobuthylmethacrylate solution, air dried and 
incubated with 3% BSA in PBS. The plates were then incubated with either 
rHIgM22 or Human IgM (negative control) at 5 μg/mL in 1% BSA in PBS for 2 
hours at room temperature (RT). The plates were then incubated with a HRP-
conjugated anti Human IgM μ-chain antibody for 1 hour, RT, and developed using 
o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. 
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Figure 34.Two-dimensional separation of wild type mouse hemibrain aqueous 
phases. Aqueous phases from hemibrains from wild type mice have been analyzed. 
For each extract, amounts equivalent to 750 μg protein were loaded. The samples 
were subjected to two dimensional separation with CHCl3:CH3OH: 0.2%CaCl2 in 
H2O 50:42:11 as a solvent system for both run. To verify if the antigen sensitivity 
to alkali treatment the plates were treated for 3 hours with ammonia vapors 
between the first and the second chromatographic run (Panel B).  
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Figure 35. rHIgM22 binding to aqueous phases from wild type mice 
hemibrain after two-dimensional separation. Aqueous phases from hemibrains 
from wild type mice have been analyzed. For each extract, amounts equivalent to 
750 μg protein were loaded. Briefly, the samples were subjected to two 
dimensional separation with CHCl3:CH3OH: 0.2% CaCl2 in H2O 50:42:11 as a 
solvent system for both run. Binding of rHIgM22 to the unknown antigen was 
assessed using TLC immunostaining. Briefly, after chromatographic running, TLC 
plates were fixed with a polyisobuthylmethacrylate solution, air dried and 
incubated with 3% BSA in PBS. The plates were then incubated with either 
rHIgM22 or Human IgM (negative control) at 5 μg/mL in 1% BSA in PBS 
overnight at 4°C. The plates were then incubated with a HRP-conjugated anti 
Human IgM μ-chain antibody for 1 hour, RT, and developed using o-
phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. 
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Figure 36. rHIgM22 binding to aqueous phases from wild type mice 
hemibrain after alkali treatment. Aqueous phases from hemibrains from wild 
type mice have been analyzed. For each extract, amounts equivalent to 750 μg 
protein were loaded. Briefly, the samples were subjected to two dimensional 
separation with CHCl3:CH3OH: 0.2% CaCl2 in H2O 50:42:11 as a solvent system 
for both run. To verify if the antigen sensitivity to alkali treatment the plates were 
treated for 3 hours with ammonia vapors between the first and the second 
chromatographic run. Binding of rHIgM22 to the unknown antigen was assessed 
using TLC immunostaining. Briefly, after chromatographic running, TLC plates 
were fixed with a polyisobuthylmethacrylate solution, air dried and incubated with 
3% BSA in PBS. The plates were then incubated with either rHIgM22 or Human 
IgM (negative control) at 5 μg/mL in 1% BSA in PBS overnight at 4°C. The plates 
were then incubated with a HRP-conjugated anti Human IgM μ-chain antibody for 
1 hour, RT, and developed using o-phenylenediamine (OPD)/H2O2 in 0.05 M 
citrate-phosphate buffer pH 5.0. 
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Mass spectrometry 
 
To attempt the identification of the antigen, purified myelin was prepared from mouse 
brain. This was followed by lipid extraction, partitioning, and chromatographic 
separation of the aqueous phases. Following the chromatographic separation of the 
aqueous phases, the area corresponding to the unidentified band was scraped. The 
scraped gel was subjected to lipid extraction, dialyzed and lyophilized. The lyophilized 
samples were then resuspended in chloroform and analyzed by ESI mass spectrometry 
in negative mode (the specific conditions are reported in the section Materials and 
Methods). The full MS spectrum revealed the presence of two ions with an m/z of 662 
and 762, respectively (Figure 38). These fragments were not detected in the spectrum of 
the negative control sample, i.e. the eluate obtained from a TLC area not containing any 
compound (Figure 39). The MS/MS spectra obtained by the fragmentation of the 762 
and 662 ions show ions with an m/z of 718 and 618, respectively, indicating the loss of 
a fragment with m/z=44 consistent with an ethanolamine fragment (Figure 39). 
The results obtained (Figure 38-39) led to hypothesize that one of the molecules, 
present in the scraped area, could be a PE with fatty acid containing 26 C atoms, two 
double bonds and 2 OH groups (MW 662) or containing 32 C atoms, two double bonds 
and 3 OH groups (MW 762). The hypothetical PE structure would be consistent with 
the chemical characterization, indicating the presence in the molecule of a free amino 
group and of phosphate. The hypothesized presence of multiple hydroxylations in the 
fatty acid residues is in principle consistent with the partitioning of the molecule with a 
preferential association with the aqueous phase. Further analysis in different MS 
conditions (ionization conditions, temperature, etc.) need to be performed in order to 
confirm the identity of this molecule and of the other molecules that could be present. 
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Figure 37. ESI-MS analysis of negative control sample. After chromatographic 
run in CHCl3:CH3OH: 0.2%CaCl2 in H2O 50:42:11, the silica gel (that did not 
contain any lipid) was scraped and subjected to lipid extraction. The lipid extract 
was subjected to ESI-MS analysis. The full negative mass spectra of the m/z range 
100-2,000 is reported in the figure.  
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Figure 38. ESI-MS analysis of unknown antigen immunoreactive to rHIgM22. 
After chromatographic separation of aqueous phases from myelin, the area 
corresponding to the unidentified band was scraped and subjected to lipid 
extraction. The lipids extracted were then subjected to ESI-MS analysis. The full 
negative mass spectra of the m/z range 200-2,000 is reported in panel B. The 
hypothetical structure of the molecule analyzed is reported in panel A.  
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Figure 39. ESI MS/MS analysis of unknown antigen immunoreactive to 
rHIgM22. After chromatographic separation of aqueous phases from myelin, the 
area corresponding to the unidentified band was scraped and subjected to lipid 
extraction. The lipids extracted were then subjected to ESI MS analysis (Figure 12) 
and subsequently to ESI MS/MS. The ESI MS/MS of the ions at m/z 762 and 662 
are reported, respectively, in panel B and C. The hypothetical structure of the 
molecule after fragmentation is reported in panel A.  
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Binding to protein antigens 
 
It is reported in the literature that all remyelination-promoting antibodies, at least those 
with a known antigen, are polyreactive. For example, A2B5, a glycolipid-binding 
antibody, is able to recognize several sialylated glycosphingolipids that have in 
common a similar carbohydrate epitope [294, 324]; O4 instead is able to bind not only 
to sulfatide, but also to seminolipid, to the proligodendroblast antigen (POA), and also 
to cholesterol [297, 325-327]. Taking all this into account, western blotting analysis 
were performed using different samples, with the aim to verify if there was any 
rHIgM22 reactivity associated with proteins. Cell lysates, total lipid extracts (that could 
contain highly hydrophobic proteins or peptides), and delipidized protein pellets from 
mixed glial cells (Figure 40) and also from mice brains (wild type and ASMKO) 
(Figure 41-42) were subjected to SDS PAGE followed by immunoblotting. In the mixed 
glial cell samples rHIgM22 was able to recognize some bands with an apparent 
molecular weight around 50 kDa in the cell lysates, and another immunoreactive band 
with an apparent molecular weight around 15 kDa, in the delipidized samples. However 
the reactivity of rHIgM22 for these bands was comparable to that of control IgM. 
Neither antibody was able to recognize any antigen in the lipid extracts and in the 
delipidized samples from mice brain. Nevertheless, two rHIgM22 immunoreactive 
bands migrating between 37 and 50 kDa were present in the homogenates from mice 
brain and these bands were not reactive to the control IgM. Since the myelin-associated 
glycoprotein MAG bears a sulfated glycosylated epitope, a western blot using an anti-
MAG antibody was run on the same samples (Figure 42). MAG immunoreactive bands 
were found in all the samples, however their apparent molecular weight did not 
correspond to that of the rHIgM22 positive band.  
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Figure 40. rHIgM22 binding to cell lysate, TLE, and delipidized samples from 
mixed glial cells. Mixed glial cells at the 14th day of culture were collected. 
Part was lysed in a solution containing Triton X-100, part was lyophilized 
and subjected to lipid extraction with CHCl3:CH3OH:H2O 20:10:1 (v/v/v). 
All the samples were resuspended in modified Laemmli buffer and boiled 
for 5 minutes at 100°C before being analyzed. Proteins were separated by 
SDS-PAGE and transferred on a PVDF membrane. For the detection of 
possible rHIgM22 antigens 100 μg of cell lysate and either 100 μg or 200 μg 
of TLE and delipidized sample were loaded. The membranes were 
incubated in 5% milk in TBS-T 0.05% overnight before incubation with 5 
μg/mL rHIgM22 or Human IgM (negative control) diluted in 1% BSA in 
TBS-T 0.05% for 1 hour at RT. After washing a few times with TBS-T 
0.05%, the membranes were incubated with a HRP-conjugated anti human 
IgM μ-chain in 1% BSA in TBS-T 0.05% for 45 minutes at RT. Peroxidase 
activity was assessed through incubation with a non-radioactive light 
emitting substrate for the detection of immobilized specific antigens 
conjugated with horseradish peroxidase-linked antibodies for 2 minutes. The 
luminescent compound generated following the reaction was detected 
through exposition to a photographic film. 
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Figure 41. rHIgM22 binding to mouse brain homogenate, TLE, and 
delipidized samples. Brains from C57BL/6N mice (wild type or ASMKO) ranging 
from 7 to 10 months of age were lysed in a solution containing Triton X-100 and 
homogenized using a dounce homogenizer (10 times, tight). The homogenate was 
centrifuged for 5 minutes at 1300 rcf at 4°C and the surnatant was used for the 
analysis. To obtain TLE and delipidized sample, frozen brains from C57BL/6N 
mice ranging from 7 to 10 months of age were resusupended in water and briefly 
subjected to sonication before being lyophilized. The samples were then subjected 
to lipid extraction with CHCl3:CH3OH:H2O 20:10:1 (v/v/v). All the samples were 
resuspended in modified Laemmli buffer and boiled for 5 minutes at 100°C before 
being analyzed. Proteins were separated by SDS-PAGE and transferred on a PVDF 
membrane. For the detection of possible rHIgM22 antigens 150 μg of each sample 
were loaded. The membranes were incubated in 5% milk in TBS-T 0.05% 
overnight before incubation with 5 μg/mL rHIgM22 or Human IgM (negative 
control) diluted in 1% BSA in TBS-T 0.05% for 1 hour at RT. After washing a few 
times with TBS-T 0.05%, the membranes were incubated with a HRP-conjugated 
anti human IgM μ-chain in 1% BSA in TBS-T 0.05% for 45 minutes at RT. 
Peroxidase activity was assessed through incubation with a non-radioactive light 
emitting substrate for the detection of immobilized specific antigens conjugated 
with horseradish peroxidase-linked antibodies for 2 minutes. The luminescent 
compound generated following the reaction was detected through exposition to a 
photographic film.  
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Figure 42. rHIgM22 binding to mouse brain homogenate. Brains from 
C57BL/6N mice (wild type or ASMKO) ranging from 7 to 10 months of age 
were lysed in a solution containing Triton X-100 and homogenized using a 
dounce homogenizer (10 times, tight). The homogenate was centrifuged for 
5 minutes at 1300 rcf at 4°C and the surnatant was used for the analysis. All 
the samples were resuspended in modified Laemmli buffer and boiled for 5 
minutes at 100°C before being analyzed. Proteins were separated by SDS-
PAGE and transferred on a PVDF membrane. For the detection of possible 
rHIgM22 antigens different amounts of samples (from 25 to 100 μg protein) 
were loaded. The membranes were incubated in 5% milk in TBS-T 0.05% 
overnight before incubation with 5 μg/mL rHIgM22 or Human IgM 
(negative control) diluted in 1% BSA in TBS-T 0.05% for 1 hour at RT. 
After washing a few times with TBS-T 0,05%, the membranes were 
incubated with a HRP-conjugated anti human IgM μ-chain in 1% BSA in 
TBS-T 0.05% for 45 minutes at RT. Peroxidase activity was assessed 
through incubation with a non-radioactive light emitting substrate for the 
detection of immobilized specific antigens conjugated with horseradish 
peroxidase-linked antibodies for 2 minutes. The luminescent compound 
generated following the reaction was detected through exposition to a 
photographic film. 
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More than 100 years have passed since Charcot, Carswell, Cruveilhier and others first 
described the pathological characteristics of multiple sclerosis (MS) [328]. MS is a 
chronic inflammatory disease of the central nervous system whose hallmark is the 
development of focal plaques of demyelination, which in turn leads to diffuse 
neurodegeneration throughout the grey and white matter of the brain and spinal cord 
[329]. MS is the most common cause of non traumatic disability in young people, and 
approximately 2.5 million people worldwide are affected by this disease [237]. Despite 
its high prevalence, multiple sclerosis remains a challenging ailment to study. The 
aetiology is unknown, the pathophysiologic mechanisms are various, and the chronic 
and unpredictable course of the pathology represent a drawback when it comes to 
defining whether the positive effects of short-term treatment will be sustained [328]. In 
MS the development of focal areas of demyelination is characterized by myelin loss that 
occurs on a background of inflammation and, while as of now there is no actual cure for 
MS, the current FDA approved therapies mainly target the inflammatory component, in 
order to contain myelin damage. Some of these strategies however, for example the use 
of Fingolimod, are also able to increase the efficiency of the remyelination process 
[282-285]. In most mouse models remyelination is a spontaneous process, occurring in 
response to demyelination, and leads to functional recovery. In MS in humans, 
however, this process is poorly efficient and its failure ultimately results in axonal 
dysfunction, degeneration, and loss of sensory and motor function [203]. For this 
reason, therapies that increase the chances of the regenerative outcome of demyelination 
have been getting more and more attention recently.  
The strategies that are currently being developed to increase efficiency of remyelination 
can be grouped as follows: 1) cell transplant, involving the transplantation of 
myelination-competent cells directly into lesion sites [286, 287]; 2) promotion of repair 
by the resident CNS stem- and precursor-cell populations, through the administration of 
growth, trophic, and neuroprotective factors [289]; 3) use of CNS reactive antibodies to 
induce remyelination [6]. Two of these remyelination promoting antibodies, BIIB033 
and rHIgM22, are currently in clinical trial for MS treatment. The first is an anti-
LINGO-1 IgG acting on LINGO-1, a protein known to inhibit remyelination via RhoA 
activation, and is currently being tested in a Phase II study in RRMS (ClinicalTrial.gov: 
NCT01864148). The second antibody, instead, is an IgM sharing several features with 
naturally occurring antibodies and is currently undergoing a phase I clinical trial aimed 
to evaluate safety and tolerability in relapsing MS patients (ClinicalTrial.gov: 
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NCT02398461), after the first phase I clinical trial in MS patients was completed 
successfully (ClinicalTrial.gov: NCT01803867). This antibody, rHIgM22, first 
identified from a patient with Waldenström macroglobulinemia, has been shown to bind 
selectively to myelin and to the surface of oligodendrocytes in vitro [8, 278]. Moreover, 
there is evidence showing that this antibody is able to enter the central nervous system, 
accumulate in the demyelinated lesions, and promote remyelination in mouse models of 
chronical demyelination [7, 8]. Both the antigen recognized by rHIgM22 and the 
signaling mechanisms through which this antibody exerts its function are still unclear, 
even though, recent evidence suggests the involvement of a pathway involving Lyn and 
ERK cascade, which leads to inhibition of the apoptotic pathway and also to inhibition 
of OPCs differentiation and promotion of OPCs proliferation [305, 306]. Moreover, 
evidence suggests that Lyn activation could be subsequent to an rHIgM22 mediated 
reorganization of a signaling complex which includes Lyn, integrin αvβ3 and PDGFαR 
[10, 304]. Nevertheless, the actual binding target of rHIgM22 has yet to be identified.  
Evidence suggests that the antigen recognized by rHIgM22 could be associated with 
plasma membrane lipid rafts and that this target could be represented either by a 
sulfated glycolipid or by a multimolecular complex including a sulfated antigen. 
rHIgM22, in fact, binds the CNS tissues with a pattern similar to that of O4, an anti-
sulfatide antibody. Moreover, binding of rHIgM22 is abolished in CNS tissues from 
CST (-/-) mice, suggesting that the antigen recognized by rHIgM22 could be one or 
more CST-sulfated antigens present in myelin and on the surface of oligodendrocyte [9, 
10]. These mice are completely devoid of sulfatide, whereas other glycolipids in the 
brain, galactosylceramide included, are not significantly altered [136].  
The analysis of the binding of rHIgM22 to different amounts of sulfatide, tested in 
different conditions (incubation time, temperature, stringency, etc.) and with different 
techniques (TLC immunostaining and surface plasmon resonance assays), revealed that 
rHIgM22 is indeed able to recognize sulfatide in vitro. Moreover, SPR experiments, 
where antigen presentation is closer to the one happening in a biological membrane 
respect to TLC immunostaining, showed that the binding of this remyelination 
promoting antibody to sulfatide is specific, suggesting that sulfatide could actually be 
one of the molecular targets of rHIgM22. Interestingly, rHIgM22 is also able to 
recognize lysosulfatide, the deacylated form of sulfatide, usually present in the normal 
CNS as a minor component, but whose levels can be increased in some pathological 
conditions, such as methachromatic leukodystrophy, a demyelinating disease [315-317]. 
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Moreover, the binding of rHIgM22 to lysosulfatide not only is specific, but has an 
affinity is comparable to that exhibited for sulfatide, at least in SPR assays. In both 
cases, however, the affinity resulted quite low if compared to that of other known anti-
glycolipid antibodies, such as the anti-lactosylceramide T5A7, for their own target 
[312]. Evidence reported in the literature, on the other hand, shows that, in model 
membranes, antibody recognition of sulfatide is affected by the membrane lipid 
microenvironment. This evidence suggests that the lipid environment might play a role 
in the determination of the surface topology of sulfatide. Distinct populations of anti-
sulfatide antibodies show a different reactivity to sulfatide in a dipalmitoyl-
PC/cholesterol environment or in a sphingomyelin/cholesterol environment. Moreover, 
length and hydroxylation of fatty acid chain of PC or of SM seem to restrict the 
recognition to higher affinity antibodies [321, 322]. Interestingly, our data obtained 
using SPR assays suggests that the binding of rHIgM22 to sulfatide might be affected 
by the composition of the lipid microenvironment. In particular, the presence of either 
GalCer or cholesterol lead to a reduction of the binding of rHIgM22 to sulfatide-
containing monolayers, whereas SM and lysosulfatide have the opposite effect, 
suggesting that that the presence of different lipids, at a certain density might be 
required to allow an optimal recognition of the antigen by rHIgM22. Sulfatide topology, 
distribution and dynamics in phospholipid bilayers, however, is also affected by the 
presence of proteins that are supposed to be physiologically relevant partners of 
sulfatide, such as myelin basic protein (MBP) [330, 331]. Moreover, several studies 
highlighted a role of external factors, like the presence of soluble sulfatide binding 
proteins [332], pH [333, 334], and the presence of cations [335, 336] in the dynamics 
and distribution of sulfatide in phospholipid bilayers. This suggests that the binding of 
rHIgM22 to sulfatide in oligodendrocytes and in myelin could be affected by a plethora 
of factors, and could actually be different than the one observed in the in vitro 
experiments.  
The analysis regarding the binding of rHIgM22 was not limited to sulfatide and its 
deacylated form. Considering that glycerophospholipids in myelin represent 
approximately 43% of the total dry weight [105], the binding of rHIgM22 to several 
glycerophospholipids was assessed through TLC immunostaining. This set of 
experiments revealed no significant binding of rHIgM22 to PC, the most abundant 
phospholipid in any biological membrane, or to its deacylated form, lyso-PC, whereas a 
non specific weak binding to PE, PS and PI was observed under experimental 
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conditions similar to those used to assess binding to sulfatide. rHIgM22 also showed no 
significant binding to phosphatidyl-β-D-glucoside (PtdGlc), a lipid characterized by a 
unique fatty acid composition particularly enriched in the brain where it is highly 
expressed in the two neurogenic regions of the adult brain [161], or to other four 
uncharacterized lipids structurally related to PtdGlc.  
On the other hand, rHIgM22 showed a significant binding to phosphatidic acid (PA), 
which is not only a constituent of all cell membranes and a precursor of all neural 
membrane glycerophospholipids, but also acts as an intracellular second messenger 
regulating different signaling proteins [15, 16]. Moreover, the binding of rHIgM22 
seems to be specific, even though further analysis, with different techniques, might be 
required to confirm this.  
The binding of rHIgM22 to other myelin glycolipids, including GalCer, GlcCer, 
LacCer, SM, and several gangliosides, was also assessed, however the antibody did not 
show a significant binding to any of the aforementioned lipids.  
The binding of rHIgM22 was also observed in lipid mixtures obtained from a variety of 
relevant biological samples, including wild type, ASM (-/-), CST (+/-) and CST (-/-) 
mice brains, mouse mixed glial cells (MGC), mouse astrocytes, rat rHIgM22+ 
oligodendrocytes (OL), rat microglia, and mouse myelin. The analysis of these samples 
not only showed the presence of a double band co-migrating with the sulfatide standard, 
thus confirming the data obtained using pure sulfatide from a commercial source, but 
also revealed the presence of a second antigen in the aqueous phases of all the sample 
analyzed, including the CST (-/-) brains which lack sulfatide. The position of this 
antigen roughly corresponds to that of the lysosulfatide standard, however literature 
suggests that lysosulfatide levels are quite low in non-pathological nervous tissue. 
Moreover, the experiments performed on pure lysosulfatide indicated that the binding of 
rHIgM22, at least in a TLC immunostaining experimental setting, should be weaker 
than the one to sulfatide. Nevertheless, the signal corresponding to these bands resulted 
quite strong, suggesting that rHIgM22 might recognize this antigen with a stronger 
affinity than that to sulfatide. Interestingly, the unknown antigen is also present in 
samples devoid of oligodendrocytes, such as MGC, astrocytes and microglia, suggesting 
a possible involvement of other glial cells in the biological response mediated by 
rHIgM22. This is consistent with the observation that in isolated OPCs, PDGF is 
required for rHIgM22-mediated inhibition of apoptotic signaling and differentiation. 
PDGF is produced by neurons and astrocytes, and stimulates OPC proliferation and 
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promotes OPC survival both in vivo and in vitro. Indeed, IgM-mediated OPC 
proliferation is detectable only in cultures containing substantial amounts of astrocytes, 
microglia and OPCs (mixed glial cultures) but not in highly enriched OPC population 
[305]. Moreover, both astrocytes and microglia play a role in the rapid activation of 
OPCs that kick-start the remyelination process and in the removal of myelin debris, 
whose presence impairs remyelination [202].  
Several experiments aimed to identified the unknown rHIgM22-positive antigen found 
in aqueous phases of various samples, revealed that this lipid is positive for colorimetric 
reagents selective for free NH2 groups-containing lipids and for phosphate containing 
lipids. An analysis using a reagent for the selective detection of glycolipid was also 
performed however, while there is a reactivity, the presence of multiple bands with non 
characteristic color in that area did not allow to conclusively say whether or not the 
unknown antigen could be a glycolipid. Moreover, analysis of the aqueous phases 
through two-dimensional TLC coupled with alkali treatment revealed not only that the 
antigen is sensitive to this treatment, but also that rHIgM22 is able to recognize the 
unknown antigen even after alkali treatment, suggesting that while the antigen is 
modified by the treatment, this is not altering the motif recognized by the antibody.  
To attempt the identification of the antigen, after chromatographic separation of 
aqueous phases from mouse CNS myelin the area corresponding to the unidentified 
band was scraped and the antigen eluted from the silica gel. This purified sample was 
then analyzed through mass spectrometry. The results led to hypothesize that one of the 
molecules migrating in the area corresponding to the unknown antigen could be a PE 
with fatty acid containing 26 C atoms, two double bonds and 2 OH groups (MW 662) or 
containing 32 C atoms, two double bonds and 3 OH groups (MW 762). The 
hypothetical PE structure would be consistent with the chemical characterization, 
indicating the presence in the molecule of a free amino group and of phosphate. 
Moreover, the hypothesized presence of multiple hydroxylation in the fatty acid 
residues is consistent with the partitioning of the molecule with a preferential 
association with the aqueous phase. However, further analysis in different MS 
conditions (ionization conditions, temperature, etc.) need to be performed in order to 
confirm the identity of this molecule and of the other molecules that could be present.  
Considering that all remyelination promoting antibodies with identified antigens are 
polyreactive and that several of these antibodies recognize not only protein antigens but 
also multiple sphingolipids [202, 294, 295, 297-299, 325], it is not possible to exclude 
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that rHIgM22 might be able to recognize a protein antigen. Taking this into account, 
western blotting analysis were performed using different samples, with the aim to verify 
if there was any rHIgM22 reactivity associated with proteins. While in MGC lysates 
and delipidized samples, the bands recognized by rHIgM22 were also recognized by the 
control IgM with comparable reactivity, in mice brain homogenates rHIgM22 was able 
to recognize two antigens, migrating between 37 and 50 kDa, not reactive to the control 
IgM. Taking these results together, it cannot be excluded that rHIgM22 might be able to 
recognize a protein antigen however further analysis need to be performed to confirm it.  
Summarizing, the data so far collected demonstrate that rHIgM22 binds to sulfatide and, 
to a lesser extent, to lysosulfatide in vitro, which is in agreement with the observation 
that rHIgM22 is able to bind to myelin and to olidendrocytes, and that its binding is 
abolished in CNS tissue from CST(-/-) mice. Moreover, the binding affinity for both 
sulfatide and its deacylated derivate is low, even if the binding is specific. However, our 
data shows that the binding affinity of rHIgM22 for sulfatide can be modulated by the 
presence of other lipids suggesting a possible role of the membrane microenvironment 
in the recognition of the antigen by rHIgM22. In addition, rHIgM22 also reacts with 
phosphatidic acid, and with an unknown molecule present in lipid extracts from various 
sources, including CST knock-out mice brains, MGC, and isolated astrocytes and 
microglia. This suggests that not only sulfatide, but also other membrane lipids might 
play a role in the binding of rHIgM22 to oligodendrocytes and other cell types. 
Moreover, binding of rHIgM22 to intact cells might require a complex molecular 
arrangement, and, in particular, sulfatide might be part of the functional rHIgM22 
antigen localized at the cell surface. Understanding whether rHIgM22 effect on 
remyelination involves a lipid-organized membrane complex, and the exact identity of 
the antigen involved and their organization in this complex is of great importance. The 
identification of the binding targets of this antibody, able to promote remyelination in 
validated mouse models of MS, and the characterization of their membrane 
microenvironment could significantly contribute to the reveal the signaling mechanisms 
underlying the biological activity of rHIgM22. This, in turn, would allow to obtain a 
better comprehension of the process of (re)myelination, and of the molecular 
mechanism involved in the pathophysiology of multiple sclerosis, thus allowing to 
define new potential therapeutic targets. 
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